WO2023181996A1 - Administration device - Google Patents

Administration device Download PDF

Info

Publication number
WO2023181996A1
WO2023181996A1 PCT/JP2023/009313 JP2023009313W WO2023181996A1 WO 2023181996 A1 WO2023181996 A1 WO 2023181996A1 JP 2023009313 W JP2023009313 W JP 2023009313W WO 2023181996 A1 WO2023181996 A1 WO 2023181996A1
Authority
WO
WIPO (PCT)
Prior art keywords
administered
discharge port
substance
pressure
discharge
Prior art date
Application number
PCT/JP2023/009313
Other languages
French (fr)
Japanese (ja)
Inventor
拓心 密岡
陽一郎 岩瀬
学 有延
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2023181996A1 publication Critical patent/WO2023181996A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps

Definitions

  • the present invention relates to an administration device that intermittently administers a substance to be administered, such as a drug solution, while being left in a living body.
  • Patent Document 1 discloses an osmotic delivery device that is a continuous administration device that continuously releases a drug as an administered substance over a long period of time while being implanted in a living body.
  • the device of Patent Document 1 includes a hollow container (body part), a piston (stopper body) slidably held within the container, and an osmotic pressure engine (pressing part) that serves as a driving source for pressing the piston. , a semipermeable membrane (liquid permeation part) placed at the proximal end of the container that allows liquid components in the body fluid (extracellular fluid) to pass through to the osmotic pressure engine, and a drug pressed by a piston placed at the tip end of the container. and a delivery orifice (emission section) for emitting.
  • a semipermeable membrane liquid permeation part
  • the container is divided into two spaces by the piston: a drug storage space (second space) located on the distal end side of the container with the piston as the boundary, and a proximal end side of the container that is on the opposite side of the second space with the piston as the boundary.
  • a drug storage space second space located on the distal end side of the container with the piston as the boundary
  • a proximal end side of the container that is on the opposite side of the second space with the piston as the boundary.
  • an osmotic agent storage space (first space) located at It is configured to be able to slide toward the distal end and release the drug contained in the second space into the living body.
  • At least one embodiment of the present invention has been made in view of the above-mentioned circumstances, and specifically, an administration device that can non-electrically intermittently administer a substance to be administered while indwelling in a living body.
  • Our goal is to provide the following.
  • the administration device includes a main body portion that has a lumen capable of accommodating a substance to be administered to be released into a living body, and a main body portion having a discharge port for the substance to be administered at the tip, and a plug body that can slide in a fluid-tight manner; a pressing portion that is disposed upstream of the plug body in the inner cavity and that is continuously driven in a non-electrical manner to press the plug body downstream; When the internal pressure of the lumen reaches a predetermined release pressure, the release port is opened to allow the release of the administered substance, and a certain amount of the administered substance is released to release the administered substance.
  • the device further includes an opening/closing control unit that closes the discharge port to restrict release of the administered substance when the internal pressure of the cavity falls below the discharge pressure.
  • the present invention it is possible to non-electrically intermittently administer a substance to be administered while it is left in a living body. Therefore, it is possible to intermittently administer a drug that is preferably administered intermittently at appropriate dosing intervals without installing an electrical drive mechanism.
  • FIG. 2 is a schematic cross-sectional view of the vicinity of the tip of the administration device according to the first embodiment.
  • FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment.
  • FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment.
  • FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment.
  • It is a schematic sectional view of the administration device concerning a 2nd embodiment.
  • It is a schematic sectional view of the tip part vicinity of the administration device concerning a 2nd embodiment.
  • It is a conceptual diagram which shows the operation
  • the "tip side (downstream side)” refers to the side where the opening/closing control section is arranged in the axial direction of the main body (where the object to be administered is administered).
  • the "proximal side (upstream side)” is the side opposite to the distal end side where the liquid permeable part is arranged (the side where the liquid in the living body enters the main body part). For example, in FIG. 1, the distal end side is on the right side of the figure, and the proximal end side is on the left side of the figure.
  • the administration device 100A is indwelled in a living body, and enables intermittent administration of the substance to be administered based on predetermined administration conditions while being continuously driven non-electrically.
  • the administration device 100A releases (administers) the substance )can do.
  • the administration device 100A can perform intermittent administration over a long period of time (at least several weeks to several months, or even several years).
  • the administered substance X to be administered from the administration device 100A is a fluid composition that can be administered to a living body to be administered to produce a predetermined effect, and can be intermittently released from the device.
  • the administered substance X is, for example, a drug (liquid) for the purpose of treating a predetermined disease.
  • Medications include drugs.
  • a drug can be any physiologically or pharmacologically active substance, especially one known to be delivered to the human or animal body. Drugs affect peripheral nerves, adrenergic receptors, cholinergic receptors, skeletal muscle, cardiovascular system, smooth muscle, vascular system, synaptic sites, neuroexchanger junction sites, endocrine and hormonal systems, immune system, reproductive organs.
  • Drugs also include, but are not limited to, drugs used to treat infectious diseases, chronic pain, diabetes, autoimmune diseases, endocrine diseases, metabolic disorders, and rheumatic diseases. Additionally, drugs include peptides, proteins, polypeptides (e.g. enzymes, hormones, cytokines), nucleic acids, oligonucleotides, viruses, viral vectors, plasmids, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, cells, steroids, analgesics. , local anesthetics, antibiotic preparations, anti-inflammatory corticosteroids, ophthalmic drugs, other small molecules of pharmaceutical use, or synthetic analogs of these species, and mixtures thereof. .
  • drugs include peptides, proteins, polypeptides (e.g. enzymes, hormones, cytokines), nucleic acids, oligonucleotides, viruses, viral vectors, plasmids, nucleoproteins, polysaccharides, glycoproteins
  • the administration device 100A generally includes a main body portion 10A, a liquid permeable portion 20A, a pressing portion 30A, a stopper 40A, and an opening/closing control portion 50A.
  • the main body portion 10A is composed of a hollow cylindrical member that has an inner cavity 11A and constitutes a housing of the administration device 100A.
  • a discharge port 12A from which the substance to be administered X is discharged is formed at the tip of the main body portion 10A.
  • the liquid permeable portion 20A, the pressing portion 30A, the plug body 40A, and the opening/closing control portion 50A are arranged in this order from the base end to the distal end of the main body portion 10A.
  • the main body portion 10A has a first space Y1 and a second space Y2 with the stopper 40A as a boundary.
  • the first space Y1 is a space defined by the liquid permeable part 20A and the stopper 40A (the space between the attached end of the liquid permeable part 20A and the base end of the stopper 40A in the main body part 10A), and is a space defined by the liquid permeable part 20A and the stopper 40A. It is a space that accommodates.
  • the second space Y2 is a space defined by the stopper 40A and the opening/closing control section 50A (space between the base end of the stopper 40A and the base end of the opening/closing control section 50A), and is a space defined by the stopper 40A and the opening/closing control section 50A. This is the space where X is accommodated. Moreover, the second space Y2 constitutes a sliding area of the stopper 40A.
  • the first space Y1 and the second space Y2 expand or contract as the stopper 40A slides before and after the administration device 100A is driven. That is, when the administration device 100A starts driving, the stopper 40A slides downstream by the pressing portion 30A, and the first space Y1 gradually expands. Further, when the administration device 100A starts driving, the stopper 40A slides downstream by the pressing portion 30A, and the second space Y2 gradually becomes smaller.
  • the main body 10A is configured such that at least the lumen 11A in the sliding area of the stopper 40A is collapsed due to buckling or the like and the shape of the lumen 11A (axis It is necessary to prevent the sliding movement of the stopper 40A from being obstructed due to deformation of the cross-sectional shape (crossing the direction).
  • the constituent materials of the main body 10A include resin materials that are non-invasive or minimally invasive to living organisms and known in the medical field (acrylonitrile polymers, halogenated polymers, polyimide, polysulfone, polycarbonate, polyethylene, polypropylene, polychloride).
  • Applicable materials include iron alloys, platinum-plated iron alloys, cobalt chromium alloys, and titanium nitride-coated stainless steel.
  • the liquid permeable part 20A is arranged on the proximal end side of the main body part 10A, isolates the living body from the inside of the administration device 100A, and allows only the liquid component contained in the body fluid in the living body to pass therethrough.
  • the liquid permeable portion 20A is made of a member having a solid-liquid separation function that allows only moisture in body fluids to permeate therethrough.
  • the liquid permeable portion 20A is made of, for example, a plasticized cellulose material, reinforced polymethyl methacrylates (PMMA) such as hydroxylethyl methacrylate (HEMA), polyurethanes, polyamides, and polyether-polyamide copolymers.
  • PMMA polymethyl methacrylates
  • HEMA hydroxylethyl methacrylate
  • Semipermeable membranes constructed of materials such as elastomeric materials, such as thermoplastic copolyesters, or mixtures thereof can be applied.
  • the pressing part 30A is located downstream of the liquid permeable part 20A in the main body part 10A, and uses an osmotic pressure engine that uses the principle of osmotic pressure to swell and expand with water that has passed through the liquid permeable part 20A.
  • the stopper 40A is pushed downstream by non-electrical continuous driving.
  • the pressing portion 30A gradually swells with the water that has passed through the liquid permeable portion 20A, and slides the stopper 40A downstream by a pressing action caused by an increase in internal pressure in the first space Y1 due to this swelling.
  • the constituent material, size, etc. of the pressing part 30A can be determined as appropriate so that the pressing speed of the stopper 40A (i.e., the swelling speed of the pressing part 30A) corresponds to the administration conditions of the substance to be administered.
  • the dosing interval and dose due to intermittent dosing can be adjusted depending on the composition of the osmotic engine constituting the pressing section 30A and the shape of the semipermeable membrane constituting the liquid permeable section 20A.
  • the pressing unit 30A is not limited to an osmotic pressure engine, but may employ other configurations as long as it can be continuously driven non-electrically to press the stopper 40A toward the downstream side.
  • the plug body 40A has a columnar base 41A extending in the longitudinal direction of the main body 10A, and an annular protruding protrusion 42A protruding from the radial outer circumference of the base 41A.
  • the stopper 40A is pressed by the pressing portion 30A, moves downstream, and pushes out the object X accommodated in the second space Y2 toward the opening/closing control portion 50A.
  • the plug body 40A is located downstream of the pressing part 30A in the main body part 10A, and its outer circumferential surface is in fluid-tight contact with the inner circumferential surface of the inner cavity 11A of the main body part 10A, and the plug body 40A slides into the inner cavity 11A. Possibly located.
  • a plurality of protruding portions 42A are provided on the outer surface of the base portion 41A, and the apex portion that protrudes most outwardly contacts the inner circumferential surface of the inner cavity 11A of the main body portion 10A.
  • the protrusion 42A seals with the inner circumferential surface of the lumen 11A so that the administered substance X does not leak upstream from the stopper 40A.
  • the number and position of the protrusions 42A are not particularly limited.
  • the stopper 40A may have a configuration without the protruding portion 42A, that is, a configuration in which the outer circumferential surface of the base portion 41A directly contacts the inner circumferential surface of the inner cavity 11A to be liquid-tight.
  • the plug body 40A is made of a flexible material that maintains close contact (liquid tightness) with the inner circumferential surface of the lumen 11A of the main body portion 10A.
  • the flexible material is preferably an elastic material, and examples of the elastic material include various rubber materials such as natural rubber, isoprene rubber, butyl rubber, chloroprene rubber, nitrile-butadiene rubber, styrene-butadiene rubber, and silicone rubber.
  • styrenic elastomers such as polyethylene, polypropylene, polybutene, ⁇ -olefin copolymers, etc., liquid paraffin, process oils, and talc.
  • polyolefins such as polyethylene, polypropylene, polybutene, ⁇ -olefin copolymers, etc., liquid paraffin, process oils, and talc. Examples include mixtures of powdered inorganic materials such as , cast, and mica.
  • polyvinyl chloride elastomers, olefin elastomers, polyester elastomers, polyamide elastomers, polyurethane elastomers, and mixtures thereof can be used as constituent materials.
  • the stopper 40A only needs to have a structure that allows it to slide liquid-tightly within the inner cavity 11A. Therefore, in the plug body 40A, the base portion 41A and the protruding portion 42A may be made of a flexible material or an elastic material, or, for example, only the protruding portion 42A that contacts the inner cavity 11A may be made of an elastic material, and the base portion 41A may be made of an elastic material. It may be made of a hard material that does not have elasticity.
  • the opening/closing control section 50A includes a valve body 51A that is disposed on the distal end side of the main body section 10A and is capable of opening and closing the discharge port 12A, and a holding section 52A that holds the valve body 51A. Prepared and configured.
  • the opening/closing control unit 50A has pressure responsiveness and opens or closes the discharge port 12A depending on whether the internal pressure in the inner cavity 11A reaches a predetermined discharge pressure.
  • the opening/closing control section 50A can be configured to have the same function as an umbrella valve, which is a pressure-responsive one-way valve.
  • the valve body 51A includes a shaft portion 511A extending in the axial direction of the discharge port 12A, and an umbrella-shaped closing portion 512A formed around the distal end side of the shaft portion 511A and closing the discharge port 12A so as to cover the discharge port 12A. It consists of:
  • the valve body 51A is made of an elastic member, and when the internal pressure in the lumen 11A reaches the release pressure due to movement of the stopper 40A, a part of the closing portion 512A separates from the discharge port 12A to open the discharge port 12A. (See Figure 3B). Furthermore, when the release of a certain amount of the administered substance X is completed and the internal pressure within the lumen 11A becomes lower than the release pressure, the separated portion of the closing portion 512A returns to its original position (shape) and releases the object. Close outlet 12A (see Figure 3C). Note that the white arrows in FIGS. 3B and 3C indicate the internal pressure inside the lumen 11A, and in FIG. 3B, the internal pressure has reached the discharge pressure, and in FIG. 3C, the internal pressure is below the discharge pressure. It is expressed as.
  • the “discharge pressure” is a pressure value for intermittently discharging a predetermined amount of the administered substance X at predetermined dosing intervals when the stopper 40A pressed by the pressing part 30A moves downstream.
  • the valve body 51A of the opening/closing control section 50A is designed to at least partially move to open the discharge port 12A when the internal pressure in the inner cavity 11A reaches the discharge pressure. Therefore, in the opening/closing control unit 50A, when the internal pressure of the lumen 11A reaches the release pressure, at least a portion of the valve body 51A opens the release port 12A and can release the administered substance X.
  • the discharge pressure can be appropriately set according to the administration conditions of the substance to be administered X to be used.
  • the holding portion 52A is fixed to the inner cavity 11A and holds the shaft portion 511A of the valve body 51A.
  • the holding portion 52A is provided with one or more through holes 521A through which the object to be administered X can pass.
  • the shape and number of the through-holes 521A can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
  • the holding portion 52A can be fixed by cutting a part of the inner cavity 11A into a groove shape and fitting into this groove-shaped portion.
  • the holding portion 52A may be adhesively fixed to the inner cavity 11A using an adhesive or the like.
  • the administration device 100A according to the first embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance to be administered X to be administered.
  • FIG. 3A shows the state immediately after the administration device 100A is placed in the living body.
  • the valve body 51A is pushed by the substance X and air in the lumen 11A. A portion is separated, opening the discharge port 12A. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12A.
  • the administration device 100A when the administration of a certain amount of the substance The body 51A returns to its original position and closes the discharge port 12A.
  • administration of the substance to be administered X is stopped until the internal pressure within the lumen 11A reaches the discharge pressure again.
  • the administration device 100A can intermittently administer the substance to be administered X while being left in the living body.
  • administration device 100B in the administration device 100B according to the second embodiment, components having the same functions as those in the first embodiment described above are given the same or related symbols, detailed explanations are omitted, and configurations that are not particularly mentioned.
  • the members, method of use, etc. may be the same as those in the first embodiment described above.
  • the administration device 100B includes a main body portion 10B, a liquid permeable portion 20B, a pressing portion 30B, a stopper 40B, and an opening/closing control portion 50B.
  • the configuration of the opening/closing control section 50B is different from the configuration of the opening/closing control section 50A of the first embodiment.
  • the pressing part 30B is continuously driven non-electrically to press the stopper 40B, but it remains indwelled in the living body.
  • the device has a configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions.
  • the opening/closing control section 50B is disposed on the distal end side of the main body section 10B, and is provided with a valve body 51B that can open and close the discharge port 12B, and is fixed to the inner cavity 11B.
  • the opening/closing control section 50B has pressure responsiveness and opens or closes the discharge port 12B depending on whether the internal pressure in the inner cavity 11B reaches a predetermined discharge pressure.
  • the opening/closing control section 50B can be configured to have the same function as a duckbill valve, which is a pressure-responsive one-way valve.
  • the valve body 51B is made of an elastic member, and is made up of a pair of valve members that extend in the axial direction of the discharge port 12B and are inclined so as to gradually converge at the axial center toward the tip.
  • the base end of the valve body 51B is connected to the base 52B.
  • the tip of the valve body 51B is arranged to face the tip of the other valve body 51, and is configured to be able to approach and separate.
  • the slit 53B is formed at the tip of the valve body 51B.
  • the valve body 51B deforms and opens the slit 53B to open the discharge port 12B (see FIG. 6B). Further, when the release of a certain amount of the administered substance X is completed and the internal pressure in the lumen 11B becomes lower than the release pressure, the tip of the valve body 51B returns to its original posture (shape) before deformation. to close the slit 53B and block the discharge port 12B (see FIG. 6C). Note that the white arrows in FIGS. 6B and 6C indicate the internal pressure inside the lumen 11B, and in FIG. 6B, the internal pressure has reached the discharge pressure, and in FIG. 6C, the internal pressure is below the discharge pressure. It is expressed as.
  • the base portion 52B is fixed to the inner cavity 11B, and the base end of the valve body 51B is connected to the base portion 52B.
  • the base 52B is provided with a liquid passage port 54B through which the substance to be administered X can pass.
  • the liquid passage port 54B is connected to the slit 53B via a flow path 55B formed inside the valve body 51B.
  • the shape and number of the liquid passage ports 54B can be appropriately set in consideration of the amount of the substance to be administered per time, the viscosity of the substance to be administered, and the like.
  • the base 52B can be fixed by cutting a part of the inner cavity 11B into a groove and fitting into the groove.
  • the base portion 52B may be adhesively fixed to the inner cavity 11B using an adhesive or the like.
  • the administration device 100B is percutaneously introduced into a living body lumen after being filled with the substance X to be administered.
  • FIG. 6A shows the state immediately after the administration device 100B is placed in the living body.
  • the valve body 51B is pushed by the object X and air in the lumen 11B.
  • the tip portions are deformed and separated, opening the discharge port 12B.
  • a certain amount of the administered substance X is administered into the living body from the opened discharge port 12B.
  • the administration device 100B when the administration of a certain amount of the substance It weakens, the valve body 51B returns to its original position, and the tip of the valve body 51B closes, thereby closing the discharge port 12B.
  • administration of the substance to be administered X is stopped until the internal pressure within the lumen 11B reaches the discharge pressure again.
  • the administration device 100B can intermittently administer the substance to be administered X while being left in the living body.
  • constituent elements having the same functions as those in the first embodiment and the second embodiment described above are given the same or related numerals, and detailed explanations are omitted. Configurations, members, usage methods, etc. that are not particularly mentioned may be the same as those in the first embodiment described above.
  • the administration device 100C includes a main body portion 10C, a liquid permeable portion 20C, a pressing portion 30C, a stopper 40C, and an opening/closing control portion 50C.
  • the configuration of the opening/closing control section 50C is different from the configuration of the opening/closing control section 50A of the first embodiment and the opening/closing control section 50B of the second embodiment.
  • the pressing portion 30C is continuously driven non-electrically to press the stopper 40C.
  • the device has a device configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions while it remains in the body.
  • the opening/closing control section 50C is disposed on the distal end side of the main body section 10C, and is provided with a valve body 51C that can open and close the discharge port 12C, and a liquid passage port 53C for the administered substance X.
  • the valve body 52C is configured to include a base 52C, and a tensioning portion 54C, which has one end connected to the valve body 51C and the other end connected to the base 52C, and which pulls the valve body 51C toward the discharge port 12C with a tensile force weaker than the discharge pressure. Ru.
  • the opening/closing control section 50C opens or closes the discharge port 12C depending on whether the internal pressure in the inner cavity 11C reaches a predetermined discharge pressure.
  • the valve body 51C is composed of a plate-like member that covers and closes the discharge port 12C.
  • the valve body 51C is connected to the tension portion 54C and is pulled toward the discharge port 12C with a tensile force that is weaker than the discharge pressure.
  • the valve body 51C covers the release port 12C and maintains the closed state due to the tensile action of the tension portion 54C.
  • the shape and material of the valve body 51C are not particularly limited as long as the valve body 51C has properties that can cut off communication between the inner cavity 11C and the outside when closed.
  • valve body 51C moves in a direction away from the release port 12C against the tensile force of the tensioning portion 54C to open the release port 12C (see FIG. 9B). ). Further, when the discharge of a certain amount of the administered substance X is completed and the internal pressure in the inner cavity 11C becomes lower than the discharge pressure, the valve body 51C is pulled by the tensioning action of the tension portion 54C, and the discharge port 12C is pulled. (see Figure 9C). Note that the white arrows in FIGS. 9B and 9C indicate the internal pressure in the inner cavity 11C, and in FIG. 9B, the internal pressure has reached the discharge pressure, and in FIG. 9C, the internal pressure is below the discharge pressure. It is expressed as.
  • the base portion 52C is fixed to the inner cavity 11C and connected to the valve body 51C via the tension portion 54C.
  • the base 52C is provided with a liquid passage port 53C through which the object X pressed by the stopper 40C can pass.
  • the shape and number of the liquid passage ports 53C can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
  • the base 52C can be fixed by cutting a part of the inner cavity 11C into a groove and fitting into the groove.
  • the base portion 52C may be adhesively fixed to the inner cavity 11C using an adhesive or the like.
  • the tension portion 54C has one end connected to the valve body 51C, the other end connected to the base portion 52C, and is made of an elastic member that can be elastically contracted like a torsion coil spring.
  • the tensioning portion 54C pulls the valve body 51C toward the discharge port 12C with a tensile force (elastic contraction force) that is weaker than the pressing force due to the discharge pressure.
  • a tensile force elastic contraction force
  • the valve body 51C pulled by the tensioning part 54C is pressed in a direction away from the outlet 12C to open the outlet 12C, and the internal pressure in the inner cavity 11C is released.
  • the tensioning force of the tensioning portion 54C pulls the discharge port 12C toward the discharge port 12C, thereby closing the discharge port 12C.
  • the administration device 100C according to the third embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance X to be administered.
  • FIG. 9A shows the state immediately after the administration device 100C is placed in the living body.
  • the valve body 51C is pushed by the object X and air in the lumen 11C. It moves in a direction away from the discharge port 12C against the tensile force of the tension portion 54C to open the discharge port 12C. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12C.
  • the valve body 51C is pulled toward the discharge port 12C by the tensioning action of the tension portion 54C, thereby closing the discharge port 12C.
  • administration of the substance to be administered X is stopped until the internal pressure in the lumen 11C reaches the discharge pressure again.
  • the administration device 100D according to the fourth embodiment is a modification of the third embodiment described above, and the operation mode during intermittent administration is the same. Therefore, constituent elements having the same functions as those in the third embodiment are given the same or related reference numerals, and detailed explanations are omitted. It may be similar to the embodiment.
  • the administration device 100D includes a main body portion 10D, a liquid permeable portion 20D, a pressing portion 30D, a stopper 40D, and an opening/closing control portion 50D.
  • the configuration of the opening/closing control section 50D is different from the configuration of the opening/closing control section 50C of the third embodiment.
  • the pressing portion 30D is continuously driven non-electrically to press the stopper 40D, as in the administration devices 100A to 100C of the first to third embodiments.
  • the device has a device configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions while it remains in the body.
  • the opening/closing control section 50D is disposed on the distal end side of the main body section 10D, and is provided with a valve body 51D that can open and close the discharge port 12D, and a liquid passage port 53D for the administered substance X.
  • the valve body 52D is configured to include a base 52D, and a tensioning portion 54D, which has one end connected to the valve body 51D and the other end connected to the base 52D, and which pulls the valve body 51D toward the discharge port 12D with a tensile force weaker than the discharge pressure. Ru.
  • the opening/closing control unit 50D opens or closes the discharge port 12D depending on whether the internal pressure within the lumen 11D reaches a predetermined discharge pressure.
  • the valve body 51D is composed of a plate-like member that covers and closes the discharge port 12D.
  • the valve body 51D is connected to the tensioning portion 54D and is pulled toward the discharge port 12D with a tensile force that is weaker than the discharge pressure.
  • the valve body 51D covers the release port 12D and maintains the closed state due to the tensile action of the tension portion 54D.
  • the shape and constituent material of the valve body 51D are not particularly limited as long as the valve body 51D has properties that can cut off communication between the inner cavity 11D and the outside when closed.
  • the valve body 51D moves in a direction away from the release port 12D against the tensile force of the tensioning portion 54D to open the release port 12D (see FIG. 12B). ). Further, when the discharge of a certain amount of the administered substance X is completed and the internal pressure in the inner cavity 11D becomes lower than the discharge pressure, the valve body 51D is pulled by the tensioning action of the tensioning portion 54D, and the discharge port 12D is pulled. (see Figure 12C). Note that the white arrows in FIGS. 12B and 12C indicate the internal pressure inside the lumen 11D, and in FIG. 12B, the internal pressure has reached the discharge pressure, and in FIG. 12C, the internal pressure is below the discharge pressure. It is expressed as.
  • the base portion 52D is fixed to the inner cavity 11D and connected to the valve body 51D via the tension portion 54D.
  • the base 52D is provided with a liquid passage port 53D through which the object X pressed by the stopper 40D can pass.
  • the shape and number of the liquid passage ports 53D can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
  • the base 52D can be fixed by cutting a part of the inner cavity 11D into a groove and fitting into the groove.
  • the base portion 52D may be adhesively fixed to the inner cavity 11D using an adhesive or the like.
  • the tension portion 54D is composed of a first magnetic body 541D connected to the valve body 51D and a base portion 52D.
  • the base 52 functions as a second magnetic body 542D.
  • the first magnetic body 541D is fitted into a non-magnetic support portion 521D extending from the base 52D to the distal end side, and is arranged so as to be relatively movable along the axial direction of the inner cavity 11D.
  • the first magnetic body 541D and the second magnetic body 542D have different magnetic poles (N pole or S pole), and generate a tensile force (magnetic attractive force) that is weaker than the discharge pressure.
  • the administration device 100D according to the fourth embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance to be administered X to be administered.
  • FIG. 12A shows the state immediately after the administration device 100D is placed in the living body.
  • the valve body 51D is pushed by the substance X and air in the lumen 11D,
  • the discharge port 12D is opened by moving in a direction away from the discharge port 12D against the tensile force of the tension portion 54D. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12D.
  • the administration device 100D when the administration of a certain amount of the object X is finished and the internal pressure in the lumen 11D becomes lower than the discharge pressure, the pressing force of the air in the lumen 11D weakens. Therefore, the valve body 51D is pulled toward the discharge port 12D by the tensioning action of the tension portion 54D, thereby closing the discharge port 12D. In the administration device 100D, administration of the substance to be administered X is stopped until the internal pressure within the lumen 11D reaches the discharge pressure again. By repeatedly performing the above-described series of operations, the administration device 100D can intermittently administer the substance to be administered while the administration device 100D is left in the living body.
  • the administration devices 100A to 100D have internal cavities 11A to 11D that can accommodate the administered substance X to be released into the living body, and have a discharge port for the administered substance X at the tip. 12A to 12D are formed, plugs 40A to 40D that can slide liquid-tightly inside the lumens 11A to 11D, and plugs 40A to 40D that are upstream of the plugs 40A to 40D in the lumens 11A to 11D.
  • Pressing parts 30A to 30D are arranged and continuously driven non-electrically to push the stoppers 40A to 40D downstream, and pressure parts 30A to 30D are arranged at the distal ends of the main bodies 10A to 10D to maintain the internal pressure of the lumens 11A to 11D at a predetermined level.
  • the discharge pressure reaches the discharge pressure, the discharge ports 12A to 12D are opened to allow the discharge of the administered substance , opening/closing control units 50A to 50D that close the discharge ports 12A to 12D to restrict release of the administered substance X.
  • the administration devices 100A to 100D utilize the structure of a conventional continuous administration device, and have opening/closing control sections 50A to 50D arranged on the distal end side of the main body sections 10A to 10D instead of the ejection section.
  • the pressing parts 30A to 30D of the administration devices 100A to 100D are configured to be non-electrically driven continuously, and the opening/closing control parts 50A to 50D have pressure responsiveness, so that the internal pressure within the lumens 11A to 11D is controlled by the administered body. It is activated when a release pressure set according to the administration conditions of the substance X is reached, and the substance to be administered can be intermittently released into the living body.
  • the administration devices 100A to 100D are capable of intermittently administering a substance to be administered which is preferably administered intermittently at appropriate administration intervals without being equipped with an electrical drive mechanism.
  • the administration devices 100A to 100D are effective from a manufacturing point of view because they utilize the conventional device configuration and require only a partial change in the tip portion.
  • the opening/closing control unit 50A is formed around a shaft portion 511A extending in the axial direction of the discharge port 12A and a distal end side of the shaft portion 511A, and covers the discharge port 12A.
  • the internal pressure of the lumen 11A reaches the release pressure
  • a part of the occlusion part 512A separates from the ejection port 12A to open the ejection port 12A, and the object to be administered X is released.
  • a part of the closing portion 512A may approach the release port 12A and close the release port 12A.
  • the administration device 100A when the internal pressure in the lumen 11A reaches the release pressure, a part of the closing part 512A opens the release port 12A to allow the release of the administered substance X, and the internal pressure is reduced.
  • the discharge pressure is lower than the discharge pressure, the separated portion of the closing portion 512A can close the discharge port 12A and restrict the discharge of the administered substance X. Therefore, although the administration device 100A is configured to be continuously driven non-electrically, it is possible to intermittently administer the substance to be administered X while remaining in the living body.
  • the opening/closing control unit 50B includes a pair of valve bodies 51B that extend in an inclined manner so as to gradually converge at the axial center toward the distal end, and a distal end of the valve body 51B. It includes an openable and closable slit 53B formed by contacting each other, a liquid passage port 54B provided on the side into which the administered substance X flows, and a flow path 55B connecting the liquid passage port 54B to the slit 53B.
  • the slit 53B opens due to the deformation of the valve body 51B, opening the discharge port 12B.
  • the valve body It may be configured such that 51B returns to its pre-deformed shape and slit 53B closes to close discharge port 12B.
  • the administration device 100B when the internal pressure in the lumen 11B reaches the release pressure, the distal end portion of the valve body 51B is separated, the slit 53B is opened, the release port 12B is opened, and the administered material X is released.
  • the tip of the valve body 51B returns to the shape before deformation, the slit 53B closes, and the release port 12B is closed to restrict the release of the administered substance X. Can be done. Therefore, although the administration device 100B is configured to be continuously driven non-electrically, it is possible to intermittently administer the substance to be administered X while remaining in the living body.
  • the opening/closing control units 50C and 50D include valve bodies 51C and 51D that close to cover the discharge ports 12C and 12D, a liquid passage port 53C for the administered object X, 53D are provided, one end is connected to the valve body 51C, 51D, the other end is connected to the base 52C, 52D, and the valve body 51C, 51D is connected to the discharge port 12C, with a tensile force weaker than the discharge pressure.
  • the valve bodies 51C and 51D are separated from the discharge ports 12C and 12D, and the valve bodies 51C and 51D are separated from the discharge ports 12C and 12D.
  • the valve bodies 51C and 51D approach the discharge ports 12C and 12D to close the discharge ports 12C and 12D. Good too.
  • the valve bodies 51C and 51D are separated from the release port 12A to allow the release of the administered substance X.
  • the release ports 12C and 12D can be closed by the valve bodies 51C and 51D due to the tensioning action of the tension portions 54C and 54D, thereby restricting the release of the administered substance X. Therefore, although the administration devices 100C and 100D are configured to be continuously driven non-electrically, they can intermittently administer the substance to be administered while remaining in the living body.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

[Problem] To administer a substance to be administered in a non-electric and intermittent manner while being placed in a living body. [Solution] An administration device 100A comprises: a body portion 10A that has a lumen 11A capable of containing a substance X to be administered that is to be released into a living body, the body portion 10A having a release opening 12A formed in the tip thereof for the substance X to be administered; a plug 40A that can slide in the lumen 11A in a liquid-tight manner; a pressing portion 30A that is disposed upstream of the plug 40A in the lumen 11A and that is continuously driven in a non-electric manner to press the plug 40A downstream; and an open/close control portion 50A that is disposed on the tip side of the body portion 10A, and that, when the internal pressure of the lumen 11A reaches a predetermined release pressure, opens the release opening 12A to permit the release of the substance X to be administered. When a predetermined amount of the substance X to be administered has been released and the internal pressure of the lumen 11A drops below the release pressure, the open/close control portion 50A closes the release opening 12A to limit the release of the substance X to be administered.

Description

投与装置dosing device
 本発明は、生体内に留置した状態で薬液などの被投与物を間欠的に投与する投与装置に関する。 TECHNICAL FIELD The present invention relates to an administration device that intermittently administers a substance to be administered, such as a drug solution, while being left in a living body.
 特許文献1には、生体内に埋め込まれた状態で被投与物である薬物を長期間に亘って持続的に長期徐放する持続投与装置である浸透圧式送達装置について開示されている。 Patent Document 1 discloses an osmotic delivery device that is a continuous administration device that continuously releases a drug as an administered substance over a long period of time while being implanted in a living body.
 特許文献1の装置は、中空の容器(本体部)と、容器内で摺動可能に保持されるピストン(栓体)と、ピストンを押圧するための駆動源となる浸透圧エンジン(押圧部)と、容器の基端側に配置され体液(細胞外液)中の液体成分を浸透圧エンジンに透過させる半透膜(液体透過部)と、容器の先端側に配置されピストンで押圧された薬物を放出する送達オリフィス(放出部)と、で概略構成される。容器は、ピストンによって2つの空間に区画され、ピストンを境に容器の先端側に位置する薬物収容空間(第2空間)と、ピストンを境に第2空間と反対側となる容器の基端側に位置する浸透圧剤収容空間(第1空間)と、を有し、浸透圧の原理を利用して半透膜を透過した体液中の液体成分による第1空間の内圧上昇に伴ってピストンを先端側に摺動させ、第2空間内に収容された薬物を生体内に放出可能に構成される。 The device of Patent Document 1 includes a hollow container (body part), a piston (stopper body) slidably held within the container, and an osmotic pressure engine (pressing part) that serves as a driving source for pressing the piston. , a semipermeable membrane (liquid permeation part) placed at the proximal end of the container that allows liquid components in the body fluid (extracellular fluid) to pass through to the osmotic pressure engine, and a drug pressed by a piston placed at the tip end of the container. and a delivery orifice (emission section) for emitting. The container is divided into two spaces by the piston: a drug storage space (second space) located on the distal end side of the container with the piston as the boundary, and a proximal end side of the container that is on the opposite side of the second space with the piston as the boundary. an osmotic agent storage space (first space) located at It is configured to be able to slide toward the distal end and release the drug contained in the second space into the living body.
特開2017-57212号公報JP 2017-57212 Publication
 ところで、被投与物の中には、例えば核酸医薬のように連続投与ではなく投与期間中に少量を間欠投与(投与と投与停止を繰り返す投与方式)した方が適切なものもある。しかし、特許文献1の装置を含む従来の持続投与装置では、被投与物を所定期間に連続して投与(徐放)することを目的としたデバイスであるため間欠投与に対応することはできない。 Incidentally, there are some substances to be administered, such as nucleic acid medicines, for which it is more appropriate to administer a small amount intermittently during the administration period (an administration method that repeats administration and stoppage) rather than continuous administration. However, conventional continuous administration devices, including the device of Patent Document 1, cannot handle intermittent administration because they are devices intended to continuously administer (sustained release) a substance to be administered over a predetermined period of time.
 被投与物の間欠投与を実現するため、従来の持続投与装置を改良し、小型モーターなどの電気的な駆動機構により栓体を間欠駆動させる構成も想定し得る。しかし、数センチ程度と小型な持続投与装置内に収容可能なサイズで間欠投与用の電動機構を製造・搭載するのは、製造上の観点から実現性に乏しい。 In order to achieve intermittent administration of the substance to be administered, it is also possible to consider a configuration in which the conventional continuous administration device is improved and the stopper is intermittently driven by an electric drive mechanism such as a small motor. However, from a manufacturing standpoint, it is difficult to manufacture and mount an electric mechanism for intermittent dosing in a size that can be accommodated in a continuous dosing device as small as several centimeters.
 本発明の少なくとも一実施形態は、上述の事情に鑑みてなされたものであり、具体的には、生体内に留置された状態で被投与物を非電気的に間欠投与することができる投与装置を提供することにある。 At least one embodiment of the present invention has been made in view of the above-mentioned circumstances, and specifically, an administration device that can non-electrically intermittently administer a substance to be administered while indwelling in a living body. Our goal is to provide the following.
 本実施形態に係る投与装置は、生体内に放出される被投与物が収容可能な内腔を有し、先端に前記被投与物の放出口が形成される本体部と、前記内腔内を液密に摺動可能な栓体と、前記内腔において前記栓体より上流側に配置され、非電気的に連続駆動して前記栓体を下流側に押圧する押圧部と、前記本体部の先端側に配置され、前記内腔の内圧が所定の放出圧力に達すると、前記放出口を開放して前記被投与物の放出を許容し、一定量の前記被投与物を放出して前記内腔の内圧が前記放出圧力を下回ると、前記放出口を閉塞して前記被投与物の放出を制限する開閉制御部と、を備える。 The administration device according to the present embodiment includes a main body portion that has a lumen capable of accommodating a substance to be administered to be released into a living body, and a main body portion having a discharge port for the substance to be administered at the tip, and a plug body that can slide in a fluid-tight manner; a pressing portion that is disposed upstream of the plug body in the inner cavity and that is continuously driven in a non-electrical manner to press the plug body downstream; When the internal pressure of the lumen reaches a predetermined release pressure, the release port is opened to allow the release of the administered substance, and a certain amount of the administered substance is released to release the administered substance. The device further includes an opening/closing control unit that closes the discharge port to restrict release of the administered substance when the internal pressure of the cavity falls below the discharge pressure.
 本発明の少なくとも一実施形態によれば、生体内に留置された状態で被投与物を非電気的に間欠投与することができる。そのため、電気的な駆動機構を搭載することなく、間欠投与が好ましい被投与物を適切な投与間隔で間欠投与することができる。 According to at least one embodiment of the present invention, it is possible to non-electrically intermittently administer a substance to be administered while it is left in a living body. Therefore, it is possible to intermittently administer a drug that is preferably administered intermittently at appropriate dosing intervals without installing an electrical drive mechanism.
第1実施形態に係る投与装置の概略断面図である。It is a schematic sectional view of the administration device concerning a 1st embodiment. 第1実施形態に係る投与装置の先端部近傍の概略断面図である。FIG. 2 is a schematic cross-sectional view of the vicinity of the tip of the administration device according to the first embodiment. 第1実施形態に係る投与装置の動作を示す概念図である。FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment. 第1実施形態に係る投与装置の動作を示す概念図である。FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment. 第1実施形態に係る投与装置の動作を示す概念図である。FIG. 3 is a conceptual diagram showing the operation of the administration device according to the first embodiment. 第2実施形態に係る投与装置の概略断面図である。It is a schematic sectional view of the administration device concerning a 2nd embodiment. 第2実施形態に係る投与装置の先端部近傍の概略断面図である。It is a schematic sectional view of the tip part vicinity of the administration device concerning a 2nd embodiment. 第2実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 2nd Embodiment. 第2実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 2nd Embodiment. 第2実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 2nd Embodiment. 第3実施形態に係る投与装置の概略断面図である。It is a schematic sectional view of the administration device concerning a 3rd embodiment. 第3実施形態に係る投与装置の先端部近傍の概略断面図である。It is a schematic sectional view of the tip part vicinity of the administration device concerning a 3rd embodiment. 第3実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 3rd Embodiment. 第3実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 3rd Embodiment. 第3実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 3rd Embodiment. 第4実施形態に係る投与装置の概略断面図である。It is a schematic sectional view of the administration device concerning a 4th embodiment. 第4実施形態に係る投与装置の先端部近傍の概略断面図である。It is a schematic sectional view of the tip part vicinity of the administration device concerning a 4th embodiment. 第4実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 4th Embodiment. 第4実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 4th Embodiment. 第4実施形態に係る投与装置の動作を示す概念図である。It is a conceptual diagram which shows the operation|movement of the administration device based on 4th Embodiment.
 以下、本発明を実施するための形態について、図面を参照しながら詳細に説明する。ここで示す実施形態は、本発明の技術的思想を具体化するために例示するものであって、本発明を限定するものではない。また、本発明の要旨を逸脱しない範囲で当業者などにより考え得る実施可能な他の形態、実施例および運用技術などは全て本発明の範囲、要旨に含まれると共に、特許請求の範囲に記載された発明とその均等の範囲に含まれる。 Hereinafter, embodiments for carrying out the present invention will be described in detail with reference to the drawings. The embodiments shown here are exemplified to embody the technical idea of the present invention, and are not intended to limit the present invention. In addition, all other possible embodiments, examples, operational techniques, etc. that can be considered by those skilled in the art without departing from the gist of the present invention are included within the scope and gist of the present invention, and are described in the claims. inventions and their equivalents.
 さらに、本明細書に添付する図面は、図示と理解のしやすさの便宜上、適宜縮尺、縦横の寸法比、形状などについて、実物から変更し模式的に表現される場合があるが、あくまで一例であって、本発明の解釈を限定するものではない。 Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented schematically by changing the scale, vertical/width dimensional ratio, shape, etc. from the actual thing as appropriate, but these are merely examples. However, this does not limit the interpretation of the present invention.
 また、以下の説明において、「第1」、「第2」のような序数詞を付して説明する場合は、特に言及しない限り、便宜上用いるものであって何らかの順序を規定するものではない。 In addition, in the following description, when ordinal numbers such as "first" and "second" are used for explanation, unless otherwise stated, they are used for convenience and do not define any order.
 以下に説明する第1~第4実施形態に係る投与装置において、「先端側(下流側)」とは、本体部の軸方向において開閉制御部が配置される側(被投与物が投与される側)であり、「基端側(上流側)」とは、先端側と反対側であって液体透過部が配置される側(生体内の液体が本体部内に進入する側)とする。例えば、図1において、先端側は図中右側となり、基端側は図中左側となる。 In the administration devices according to the first to fourth embodiments described below, the "tip side (downstream side)" refers to the side where the opening/closing control section is arranged in the axial direction of the main body (where the object to be administered is administered). The "proximal side (upstream side)" is the side opposite to the distal end side where the liquid permeable part is arranged (the side where the liquid in the living body enters the main body part). For example, in FIG. 1, the distal end side is on the right side of the figure, and the proximal end side is on the left side of the figure.
 [第1実施形態]
 第1実施形態に係る投与装置100Aについて説明する。投与装置100Aは、生体内に留置され、非電気的に連続駆動しつつ所定の投与条件に基づき被投与物Xの間欠投与を可能とする。
[First embodiment]
An administration device 100A according to the first embodiment will be described. The administration device 100A is indwelled in a living body, and enables intermittent administration of the substance to be administered based on predetermined administration conditions while being continuously driven non-electrically.
 投与装置100Aは、生体内に被投与物Xを間欠投与するため、所定の投与条件(投与期間、投与タイミング、投与量などの投与に関する諸条件)で被投与物Xを生体内に放出(投与)することができる。投与装置100Aは、長期間(少なくとも数週間~数か月、さらには数年間)に亘って間欠投与することができる。 The administration device 100A releases (administers) the substance )can do. The administration device 100A can perform intermittent administration over a long period of time (at least several weeks to several months, or even several years).
 投与装置100Aから投与する被投与物Xは、投与対象となる生体に投与して所定の効果発現が得られ、かつ間欠的に装置から放出可能な流体組成物である。被投与物Xは、一例として、所定の疾患の治療を目的とする薬剤(液剤)である。薬剤は、薬物を含む。薬物は、任意の生理学的にまたは薬理学的に活性な物質であり、特にヒトまたは動物の体に送達されることが知られるものであり得る。薬物は、末梢神経、アドレナリン受容体、コリン作動性受容体、骨格筋、心臓血管系、平滑筋、血管系、シナプス(synoptic)部位、神経交換器接合部位、内分泌およびホルモン系、免疫系、生殖器系、骨格系、局所ホルモン系、消化器および排泄系、ヒスタミン系、または中枢神経系に作用する薬物を含むが、これらに限定されない。また、薬物は、感染症、慢性痛、糖尿病、自己免疫疾患、内分泌疾患、代謝異常、およびリウマチ性疾患の治療に用いられる薬物を含むが、これらに限定されない。さらに、薬物は、ペプチド、タンパク質、ポリペプチド(例えば、酵素、ホルモン、サイトカイン)、核酸、オリゴヌクレオチド、ウィルス、ウィルスベクター、プラスミド、核タンパク質、多糖、糖タンパク質、リポタンパク質、細胞、ステロイド、鎮痛薬、局所麻酔薬、抗生物質製剤、抗炎症性コルチコステロイド、眼薬、製薬学的用途の他の小分子、またはこれらの種の合成アナログ、およびこれらの混合物などを含むが、これらに限定されない。 The administered substance X to be administered from the administration device 100A is a fluid composition that can be administered to a living body to be administered to produce a predetermined effect, and can be intermittently released from the device. The administered substance X is, for example, a drug (liquid) for the purpose of treating a predetermined disease. Medications include drugs. A drug can be any physiologically or pharmacologically active substance, especially one known to be delivered to the human or animal body. Drugs affect peripheral nerves, adrenergic receptors, cholinergic receptors, skeletal muscle, cardiovascular system, smooth muscle, vascular system, synaptic sites, neuroexchanger junction sites, endocrine and hormonal systems, immune system, reproductive organs. the skeletal system, the local hormonal system, the digestive and excretory system, the histamine system, or the central nervous system. Drugs also include, but are not limited to, drugs used to treat infectious diseases, chronic pain, diabetes, autoimmune diseases, endocrine diseases, metabolic disorders, and rheumatic diseases. Additionally, drugs include peptides, proteins, polypeptides (e.g. enzymes, hormones, cytokines), nucleic acids, oligonucleotides, viruses, viral vectors, plasmids, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, cells, steroids, analgesics. , local anesthetics, antibiotic preparations, anti-inflammatory corticosteroids, ophthalmic drugs, other small molecules of pharmaceutical use, or synthetic analogs of these species, and mixtures thereof. .
 投与装置100Aは、図1に示すように、概説すると、本体部10Aと、液体透過部20Aと、押圧部30Aと、栓体40Aと、開閉制御部50Aと、を備える。 As shown in FIG. 1, the administration device 100A generally includes a main body portion 10A, a liquid permeable portion 20A, a pressing portion 30A, a stopper 40A, and an opening/closing control portion 50A.
 本体部10Aは、内腔11Aを有し、投与装置100Aの筐体を構成する中空の筒状部材で構成される。本体部10Aの先端には、被投与物Xを放出する放出口12Aが形成されている。液体透過部20A、押圧部30A、栓体40A、および開閉制御部50Aは、本体部10Aの基端から先端に向かって順に配置される。 The main body portion 10A is composed of a hollow cylindrical member that has an inner cavity 11A and constitutes a housing of the administration device 100A. A discharge port 12A from which the substance to be administered X is discharged is formed at the tip of the main body portion 10A. The liquid permeable portion 20A, the pressing portion 30A, the plug body 40A, and the opening/closing control portion 50A are arranged in this order from the base end to the distal end of the main body portion 10A.
 本体部10Aは、栓体40Aを境に第1空間Y1と、第2空間Y2と、を有する。第1空間Y1は、液体透過部20Aと栓体40Aにより区画される空間(本体部10Aにおける液体透過部20Aの装着端から栓体40Aの基端との間の空間)であり、押圧部30Aが収容される空間である。第2空間Y2は、栓体40Aと開閉制御部50Aにより区画される空間(栓体40Aの基端と開閉制御部50Aの基端との間の空間)であり、栓体40Aおよび被投与物Xが収容される空間である。また、第2空間Y2は、栓体40Aの摺動領域を構成する。 The main body portion 10A has a first space Y1 and a second space Y2 with the stopper 40A as a boundary. The first space Y1 is a space defined by the liquid permeable part 20A and the stopper 40A (the space between the attached end of the liquid permeable part 20A and the base end of the stopper 40A in the main body part 10A), and is a space defined by the liquid permeable part 20A and the stopper 40A. It is a space that accommodates. The second space Y2 is a space defined by the stopper 40A and the opening/closing control section 50A (space between the base end of the stopper 40A and the base end of the opening/closing control section 50A), and is a space defined by the stopper 40A and the opening/closing control section 50A. This is the space where X is accommodated. Moreover, the second space Y2 constitutes a sliding area of the stopper 40A.
 第1空間Y1と第2空間Y2は、投与装置100Aの駆動前後において、栓体40Aの摺動に伴い空間が拡大または縮小する。すなわち、第1空間Y1は、投与装置100Aが駆動を開始すると、押圧部30Aによって栓体40Aが下流側へ摺動して徐々に空間が拡大する。また、第2空間Y2は、投与装置100Aが駆動を開始すると、押圧部30Aによって栓体40Aが下流側へ摺動して徐々に空間が縮小する。 The first space Y1 and the second space Y2 expand or contract as the stopper 40A slides before and after the administration device 100A is driven. That is, when the administration device 100A starts driving, the stopper 40A slides downstream by the pressing portion 30A, and the first space Y1 gradually expands. Further, when the administration device 100A starts driving, the stopper 40A slides downstream by the pressing portion 30A, and the second space Y2 gradually becomes smaller.
 本体部10Aは、栓体40Aの摺動により被投与物Xの放出精度を維持するため、少なくとも栓体40Aの摺動領域の内腔11Aが座屈などにより潰れて内腔11Aの形状(軸方向と交差する断面形状)が変形して栓体40Aの摺動が阻害されるのを防止する必要がある。本体部10Aの構成材料としては、生体に対して非侵襲若しくは低侵襲であって医療分野において公知の樹脂材料(アクリロニトリルポリマー類、ハロゲン化ポリマー類、ポリイミド、ポリスルホン、ポリカーボネート、ポリエチレン、ポリプロピレン、ポリ塩化ビニル-アクリル酸共重合体、ポリカーボネート-アクリロニトリル-ブタジエン-スチレン、およびポリスチレンなど)、金属材料(ステンレス鋼、チタン、ニッケル、アルミニウム、バナジウム、白金、タンタル、金、およびこれらの合金、並びに、金めっき合金鉄、白金めっき合金鉄、コバルトクロム合金、および窒化チタン被覆ステンレス鋼など)などが適用可能である。 In order to maintain the release accuracy of the administered substance X by sliding the stopper 40A, the main body 10A is configured such that at least the lumen 11A in the sliding area of the stopper 40A is collapsed due to buckling or the like and the shape of the lumen 11A (axis It is necessary to prevent the sliding movement of the stopper 40A from being obstructed due to deformation of the cross-sectional shape (crossing the direction). The constituent materials of the main body 10A include resin materials that are non-invasive or minimally invasive to living organisms and known in the medical field (acrylonitrile polymers, halogenated polymers, polyimide, polysulfone, polycarbonate, polyethylene, polypropylene, polychloride). vinyl-acrylic acid copolymer, polycarbonate-acrylonitrile-butadiene-styrene, and polystyrene), metal materials (stainless steel, titanium, nickel, aluminum, vanadium, platinum, tantalum, gold, and alloys thereof, and gold plating) Applicable materials include iron alloys, platinum-plated iron alloys, cobalt chromium alloys, and titanium nitride-coated stainless steel.
 液体透過部20Aは、本体部10Aの基端側に配置され、生体と投与装置100Aの内部とを隔離すると共に、生体内の体液に含まれる液体成分のみを透過させる。液体透過部20Aは、体液中の水分のみを透過させることが可能な固液分離機能を有する部材で構成される。 The liquid permeable part 20A is arranged on the proximal end side of the main body part 10A, isolates the living body from the inside of the administration device 100A, and allows only the liquid component contained in the body fluid in the living body to pass therethrough. The liquid permeable portion 20A is made of a member having a solid-liquid separation function that allows only moisture in body fluids to permeate therethrough.
 液体透過部20Aは、一例として、可塑化されたセルロース系材料、ヒドロキシルエチルメタクリレート(HEMA)のような強化ポリメチルメタクリレート類(PMMA)、並びに、ポリウレタン類およびポリアミド類、ポリエーテル-ポリアミド共重合体類、熱可塑性コポリエステル類のようなエラストマー材料などの材料、若しくはその混合物で構成される半透膜を適用することができる。 The liquid permeable portion 20A is made of, for example, a plasticized cellulose material, reinforced polymethyl methacrylates (PMMA) such as hydroxylethyl methacrylate (HEMA), polyurethanes, polyamides, and polyether-polyamide copolymers. Semipermeable membranes constructed of materials such as elastomeric materials, such as thermoplastic copolyesters, or mixtures thereof can be applied.
 押圧部30Aは、本体部10A内において液体透過部20Aよりも下流側に位置し、浸透圧の原理を利用して液体透過部20Aを透過した水分により膨潤して拡張する浸透圧エンジンを用いた非電気的な連続駆動により栓体40Aを下流側に押圧する。押圧部30Aは、液体透過部20Aを透過した水分によって徐々に膨潤し、この膨潤に伴う第1空間Y1内の内圧上昇に起因する押圧作用により栓体40Aを下流側に摺動させる。 The pressing part 30A is located downstream of the liquid permeable part 20A in the main body part 10A, and uses an osmotic pressure engine that uses the principle of osmotic pressure to swell and expand with water that has passed through the liquid permeable part 20A. The stopper 40A is pushed downstream by non-electrical continuous driving. The pressing portion 30A gradually swells with the water that has passed through the liquid permeable portion 20A, and slides the stopper 40A downstream by a pressing action caused by an increase in internal pressure in the first space Y1 due to this swelling.
 押圧部30Aは、被投与物Xの投与条件に応じた栓体40Aの押圧速度(すなわち、押圧部30Aの膨潤速度)となるように、構成材料やサイズなどを適宜決定することができる。投与装置100Aは、押圧部30Aを構成する浸透圧エンジンの組成や液体透過部20Aを構成する半透膜の形状などによって、間欠投与による投与間隔や投与量などが調整可能である。 The constituent material, size, etc. of the pressing part 30A can be determined as appropriate so that the pressing speed of the stopper 40A (i.e., the swelling speed of the pressing part 30A) corresponds to the administration conditions of the substance to be administered. In the dosing device 100A, the dosing interval and dose due to intermittent dosing can be adjusted depending on the composition of the osmotic engine constituting the pressing section 30A and the shape of the semipermeable membrane constituting the liquid permeable section 20A.
 押圧部30Aは、少なくとも非電気的に連続駆動して栓体40Aを下流側へ押圧可能な構成であれば、浸透圧エンジンに限らず、他の構成を採用してもよい。 The pressing unit 30A is not limited to an osmotic pressure engine, but may employ other configurations as long as it can be continuously driven non-electrically to press the stopper 40A toward the downstream side.
 栓体40Aは、本体部10Aの長手方向に延びる柱状の基部41Aと、基部41Aの径方向外周に突設されている環状凸条の突出部42Aと、を有する。栓体40Aは、押圧部30Aにより押圧されて下流側へ移動し、第2空間Y2内に収容される被投与物Xを開閉制御部50A側へ押し出す。栓体40Aは、本体部10A内において押圧部30Aよりも下流側に位置し、その外周面が本体部10Aの内腔11Aの内周面に液密に接すると共に、内腔11A内に摺動可能に配置されている。 The plug body 40A has a columnar base 41A extending in the longitudinal direction of the main body 10A, and an annular protruding protrusion 42A protruding from the radial outer circumference of the base 41A. The stopper 40A is pressed by the pressing portion 30A, moves downstream, and pushes out the object X accommodated in the second space Y2 toward the opening/closing control portion 50A. The plug body 40A is located downstream of the pressing part 30A in the main body part 10A, and its outer circumferential surface is in fluid-tight contact with the inner circumferential surface of the inner cavity 11A of the main body part 10A, and the plug body 40A slides into the inner cavity 11A. Possibly located.
 突出部42Aは、基部41Aの外面に複数設けられ、最も外側に突出した頂点部は、本体部10Aの内腔11Aの内周面と当接する。突出部42Aは、被投与物Xが栓体40Aよりも上流側に漏出しないように内腔11Aの内周面との間をシールする。 A plurality of protruding portions 42A are provided on the outer surface of the base portion 41A, and the apex portion that protrudes most outwardly contacts the inner circumferential surface of the inner cavity 11A of the main body portion 10A. The protrusion 42A seals with the inner circumferential surface of the lumen 11A so that the administered substance X does not leak upstream from the stopper 40A.
 なお、突出部42Aは、その配置数や配置位置は特に限定されない。また、栓体40Aは、突出部42Aを備えていない構成、すなわち基部41Aの外周面が内腔11Aの内周面に直に接触して液密とする構成でもよい。 Note that the number and position of the protrusions 42A are not particularly limited. Moreover, the stopper 40A may have a configuration without the protruding portion 42A, that is, a configuration in which the outer circumferential surface of the base portion 41A directly contacts the inner circumferential surface of the inner cavity 11A to be liquid-tight.
 栓体40Aの構成材料としては、本体部10Aの内腔11Aの内周面との密着性(液密性)を保持し、可撓性を有する材料で構成される。可撓性材料は弾性材料であることが好ましく、弾性材料としては、天然ゴム、イソプレンゴム、ブチルゴム、クロロプレンゴム、ニトリル-ブタジエンゴム、スチレン-ブタジエンゴム、シリコーンゴムなどの各種ゴム材料(特に、加硫処理したもの)や、スチレン系エラストマー、水添スチレン系エラストマー、およびこれらスチレン系エラストマーにポリエチレン、ポリプロピレン、ポリブテン、α-オレフィン共重合体などのポリオレフィンや、流動パラフィン、プロセスオイルなどのオイルやタルク、キャスト、マイカなどの粉体無機物を混合したものが挙げられる。さらに、ポリ塩化ビニル系エラストマー、オレフィン系エラストマー、ポリエステル系エラストマー、ポリアミド系エラストマー、ポリウレタン系エラストマーや、それら混合物が構成材料として使用できる。構成材料としては、特に、弾性特性を有し、γ線滅菌、電子線滅菌、高圧蒸気滅菌が可能などの観点からジエン系ゴム、スチレン系エラストマーなどを適用することができる。なお、栓体40Aは、内腔11A内を液密に摺動可能な構成を有すればよい。そのため、栓体40Aは、基部41Aおよび突出部42Aを可撓性材料或いは弾性材料で構成してもよいし、例えば内腔11Aと当接する突出部42Aのみを弾性材料で構成して基部41Aは弾性を有さない硬質材料で構成してもよい。 The plug body 40A is made of a flexible material that maintains close contact (liquid tightness) with the inner circumferential surface of the lumen 11A of the main body portion 10A. The flexible material is preferably an elastic material, and examples of the elastic material include various rubber materials such as natural rubber, isoprene rubber, butyl rubber, chloroprene rubber, nitrile-butadiene rubber, styrene-butadiene rubber, and silicone rubber. sulfur-treated), styrenic elastomers, hydrogenated styrene elastomers, and polyolefins such as polyethylene, polypropylene, polybutene, α-olefin copolymers, etc., liquid paraffin, process oils, and talc. Examples include mixtures of powdered inorganic materials such as , cast, and mica. Further, polyvinyl chloride elastomers, olefin elastomers, polyester elastomers, polyamide elastomers, polyurethane elastomers, and mixtures thereof can be used as constituent materials. As the constituent material, diene rubber, styrene elastomer, etc. can be used, especially from the viewpoint that they have elastic properties and can be sterilized by gamma rays, electron beams, or high-pressure steam. In addition, the stopper 40A only needs to have a structure that allows it to slide liquid-tightly within the inner cavity 11A. Therefore, in the plug body 40A, the base portion 41A and the protruding portion 42A may be made of a flexible material or an elastic material, or, for example, only the protruding portion 42A that contacts the inner cavity 11A may be made of an elastic material, and the base portion 41A may be made of an elastic material. It may be made of a hard material that does not have elasticity.
 開閉制御部50Aは、図2に示すように、本体部10Aの先端側に配置され、放出口12Aを開放および閉塞閉可能な弁体51Aと、弁体51Aを保持する保持部52Aと、を備えて構成される。開閉制御部50Aは、圧力応答性を有し、内腔11A内の内圧が所定の放出圧力に達したか否かに応じて放出口12Aを開放または閉塞する。開閉制御部50Aは、圧力応答式の一方向弁であるアンブレラ弁と同等の機能を有して構成することができる。 As shown in FIG. 2, the opening/closing control section 50A includes a valve body 51A that is disposed on the distal end side of the main body section 10A and is capable of opening and closing the discharge port 12A, and a holding section 52A that holds the valve body 51A. Prepared and configured. The opening/closing control unit 50A has pressure responsiveness and opens or closes the discharge port 12A depending on whether the internal pressure in the inner cavity 11A reaches a predetermined discharge pressure. The opening/closing control section 50A can be configured to have the same function as an umbrella valve, which is a pressure-responsive one-way valve.
 弁体51Aは、放出口12Aの軸方向に延在する軸部511Aと、軸部511Aの先端側の周囲に形成され、放出口12Aを覆うように閉塞する傘状の閉塞部512Aと、を含んで構成される。 The valve body 51A includes a shaft portion 511A extending in the axial direction of the discharge port 12A, and an umbrella-shaped closing portion 512A formed around the distal end side of the shaft portion 511A and closing the discharge port 12A so as to cover the discharge port 12A. It consists of:
 弁体51Aは、弾性部材で構成され、栓体40Aの移動により内腔11A内の内圧が放出圧力に達すると、閉塞部512Aの一部が放出口12Aから離隔して放出口12Aを開放する(図3Bを参照)。また、弁体51Aは、一定量の被投与物Xの放出が終了して内腔11A内の内圧が放出圧力を下回ると、閉塞部512Aの離隔部分が元の姿勢(形状)に戻って放出口12Aを閉塞する(図3Cを参照)。なお、図3B、図3Cの白抜き矢印は、内腔11A内の内圧を示しており、図3Bでは内圧が放出圧力に達し、図3Cでは内圧が放出圧力を下回っていることを矢印の大小で表現している。 The valve body 51A is made of an elastic member, and when the internal pressure in the lumen 11A reaches the release pressure due to movement of the stopper 40A, a part of the closing portion 512A separates from the discharge port 12A to open the discharge port 12A. (See Figure 3B). Furthermore, when the release of a certain amount of the administered substance X is completed and the internal pressure within the lumen 11A becomes lower than the release pressure, the separated portion of the closing portion 512A returns to its original position (shape) and releases the object. Close outlet 12A (see Figure 3C). Note that the white arrows in FIGS. 3B and 3C indicate the internal pressure inside the lumen 11A, and in FIG. 3B, the internal pressure has reached the discharge pressure, and in FIG. 3C, the internal pressure is below the discharge pressure. It is expressed as.
 「放出圧力」は、押圧部30Aに押圧された栓体40Aが下流側に移動した際、所定の投与間隔で被投与物Xを所定量だけ間欠的に放出するための圧力値である。開閉制御部50Aの弁体51Aは、内腔11A内の内圧が放出圧力に達すると、少なくとも一部が可動して放出口12Aを開放するように設計されている。そのため、開閉制御部50Aは、内腔11Aの内圧が放出圧力に達すると、弁体51Aの少なくとも一部が放出口12Aを開放して被投与物Xを放出することができる。なお、放出圧力は、使用する被投与物Xの投与条件に応じて適宜設定することができる。 The "discharge pressure" is a pressure value for intermittently discharging a predetermined amount of the administered substance X at predetermined dosing intervals when the stopper 40A pressed by the pressing part 30A moves downstream. The valve body 51A of the opening/closing control section 50A is designed to at least partially move to open the discharge port 12A when the internal pressure in the inner cavity 11A reaches the discharge pressure. Therefore, in the opening/closing control unit 50A, when the internal pressure of the lumen 11A reaches the release pressure, at least a portion of the valve body 51A opens the release port 12A and can release the administered substance X. Note that the discharge pressure can be appropriately set according to the administration conditions of the substance to be administered X to be used.
 保持部52Aは、内腔11Aに固定され、弁体51Aの軸部511Aを保持する。保持部52Aは、被投与物Xが通過可能な貫通孔521Aが1つ以上設けられている。貫通孔521Aの形状や個数については、被投与物Xの1回あたりの投与量や被投与物Xの粘性などを考慮して適宜設定することができる。 The holding portion 52A is fixed to the inner cavity 11A and holds the shaft portion 511A of the valve body 51A. The holding portion 52A is provided with one or more through holes 521A through which the object to be administered X can pass. The shape and number of the through-holes 521A can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
 保持部52Aは、図2に示すように、内腔11Aの一部を溝状に切削し、この溝状部位に嵌合させて固定することができる。保持部52Aは、内腔11Aに対し、接着剤などを用いて接着固定させてもよい。 As shown in FIG. 2, the holding portion 52A can be fixed by cutting a part of the inner cavity 11A into a groove shape and fitting into this groove-shaped portion. The holding portion 52A may be adhesively fixed to the inner cavity 11A using an adhesive or the like.
 上述した第1実施形態に係る投与装置100Aは、投与対象に対する被投与物Xを充填した後、生体管腔に対し経皮的に導入される。図3Aは、投与装置100Aを生体内に留置した直後の状態を示している。 The administration device 100A according to the first embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance to be administered X to be administered. FIG. 3A shows the state immediately after the administration device 100A is placed in the living body.
 投与装置100Aは、図3Bに示すように、栓体40Aの移動により内腔11A内の内圧が放出圧力に達すると、弁体51Aは内腔11A内の被投与物Xや空気に押されて一部が離隔し、放出口12Aを開放する。このとき、被投与物Xは、開放された放出口12Aから生体内に一定量だけ投与される。 In the administration device 100A, as shown in FIG. 3B, when the internal pressure in the lumen 11A reaches the release pressure due to movement of the stopper 40A, the valve body 51A is pushed by the substance X and air in the lumen 11A. A portion is separated, opening the discharge port 12A. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12A.
 そして、投与装置100Aは、図3Cに示すように、一定量の被投与物Xの投与が終了して内腔11A内の内圧が放出圧力を下回ると、弁体51Aに対する押圧力が弱まり、弁体51Aが元の姿勢に戻って放出口12Aを閉塞する。投与装置100Aは、内腔11A内の内圧が再び放出圧力に達するまで被投与物Xの投与は停止される。投与装置100Aは、上述した一連の動作を繰り返し行うことで、生体内に留置された状態で被投与物Xを間欠投与することができる。 Then, as shown in FIG. 3C, in the administration device 100A, when the administration of a certain amount of the substance The body 51A returns to its original position and closes the discharge port 12A. In the administration device 100A, administration of the substance to be administered X is stopped until the internal pressure within the lumen 11A reaches the discharge pressure again. By repeatedly performing the series of operations described above, the administration device 100A can intermittently administer the substance to be administered X while being left in the living body.
 [第2実施形態]
 次に、第2実施形態に係る投与装置100Bについて図4~図6を適宜参照しながら説明する。
[Second embodiment]
Next, the administration device 100B according to the second embodiment will be described with reference to FIGS. 4 to 6 as appropriate.
 なお、第2実施形態に係る投与装置100Bにおいて、前述した第1実施形態と同等の機能を有する構成要件については同一または関連する符号を付して詳細な説明を省略し、特に言及しない構成、部材、および使用方法などについては、前述した第1実施形態と同様のものとしてよい。 In addition, in the administration device 100B according to the second embodiment, components having the same functions as those in the first embodiment described above are given the same or related symbols, detailed explanations are omitted, and configurations that are not particularly mentioned. The members, method of use, etc. may be the same as those in the first embodiment described above.
 投与装置100Bは、図4に示すように、本体部10Bと、液体透過部20Bと、押圧部30Bと、栓体40Bと、開閉制御部50Bと、を備える。 As shown in FIG. 4, the administration device 100B includes a main body portion 10B, a liquid permeable portion 20B, a pressing portion 30B, a stopper 40B, and an opening/closing control portion 50B.
 第2実施形態に係る投与装置100Bは、図4や図5に示すように、開閉制御部50Bの構成が第1実施形態の開閉制御部50Aの構成と相違する。また、第2実施形態の投与装置100Bについても、第1実施形態の投与装置100Aと同様、押圧部30Bが非電気的に連続駆動して栓体40Bを押圧するが、生体内に留置したまま所定の投与条件に基づき被投与物Xの間欠的投与が可能な装置構成を有している。 In the administration device 100B according to the second embodiment, as shown in FIGS. 4 and 5, the configuration of the opening/closing control section 50B is different from the configuration of the opening/closing control section 50A of the first embodiment. In addition, in the administration device 100B of the second embodiment, as in the administration device 100A of the first embodiment, the pressing part 30B is continuously driven non-electrically to press the stopper 40B, but it remains indwelled in the living body. The device has a configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions.
 開閉制御部50Bは、図5に示すように、本体部10Bの先端側に配置され、放出口12Bを開放および閉塞閉可能な弁体51Bと、弁体51Bが設けられ内腔11Bに固定される基部52Bと、弁体51Bの先端に設けられたスリット53Bと、被投与物Xが流入する側に設けられた通液口54Bと、通液口54Bをスリット53Bに接続する流路55Bと、を備えて構成される。開閉制御部50Bは、圧力応答性を有し、内腔11B内の内圧が所定の放出圧力に達したか否かに応じて放出口12Bを開放または閉塞する。開閉制御部50Bは、圧力応答式の一方向弁であるダックビル弁と同等の機能を有して構成することができる。 As shown in FIG. 5, the opening/closing control section 50B is disposed on the distal end side of the main body section 10B, and is provided with a valve body 51B that can open and close the discharge port 12B, and is fixed to the inner cavity 11B. a base 52B, a slit 53B provided at the tip of the valve body 51B, a liquid passage port 54B provided on the side into which the administered substance X flows, and a channel 55B connecting the liquid passage port 54B to the slit 53B. , consists of. The opening/closing control section 50B has pressure responsiveness and opens or closes the discharge port 12B depending on whether the internal pressure in the inner cavity 11B reaches a predetermined discharge pressure. The opening/closing control section 50B can be configured to have the same function as a duckbill valve, which is a pressure-responsive one-way valve.
 弁体51Bは、弾性部材で構成され、先端に向かって徐々に軸中心で収束するように傾斜して放出口12Bの軸方向に延在する一対の弁部材で構成される。弁体51Bの基端は、基部52Bに接続される。弁体51Bの先端は、他方の弁体51の先端と対向して配置され、接近・離隔可能に構成される。スリット53Bは、弁体51Bの先端部で構成される。 The valve body 51B is made of an elastic member, and is made up of a pair of valve members that extend in the axial direction of the discharge port 12B and are inclined so as to gradually converge at the axial center toward the tip. The base end of the valve body 51B is connected to the base 52B. The tip of the valve body 51B is arranged to face the tip of the other valve body 51, and is configured to be able to approach and separate. The slit 53B is formed at the tip of the valve body 51B.
 弁体51Bは、栓体40Bの移動により内腔11B内の内圧が放出圧力に達すると、変形してスリット53Bが開いて放出口12Bを開放する(図6Bを参照)。また、弁体51Bは、一定量の被投与物Xの放出が終了して内腔11B内の内圧が放出圧力を下回ると、弁体51Bの先端が変形前の元の姿勢(形状)に戻ってスリット53Bを閉じて放出口12Bを閉塞する(図6Cを参照)。なお、図6B、図6Cの白抜き矢印は、内腔11B内の内圧を示しており、図6Bでは内圧が放出圧力に達し、図6Cでは内圧が放出圧力を下回っていることを矢印の大小で表現している。 When the internal pressure in the lumen 11B reaches the release pressure due to the movement of the stopper 40B, the valve body 51B deforms and opens the slit 53B to open the discharge port 12B (see FIG. 6B). Further, when the release of a certain amount of the administered substance X is completed and the internal pressure in the lumen 11B becomes lower than the release pressure, the tip of the valve body 51B returns to its original posture (shape) before deformation. to close the slit 53B and block the discharge port 12B (see FIG. 6C). Note that the white arrows in FIGS. 6B and 6C indicate the internal pressure inside the lumen 11B, and in FIG. 6B, the internal pressure has reached the discharge pressure, and in FIG. 6C, the internal pressure is below the discharge pressure. It is expressed as.
 基部52Bは、内腔11Bに固定され、弁体51Bの基端が接続される。基部52Bには、被投与物Xが通過可能な通液口54Bが設けられる。通液口54Bは、弁体51Bの内方に形成された流路55Bを介してスリット53Bと接続される。通液口54Bの形状や個数については、被投与物Xの1回あたりの投与量や被投与物Xの粘性などを考慮して適宜設定することができる。 The base portion 52B is fixed to the inner cavity 11B, and the base end of the valve body 51B is connected to the base portion 52B. The base 52B is provided with a liquid passage port 54B through which the substance to be administered X can pass. The liquid passage port 54B is connected to the slit 53B via a flow path 55B formed inside the valve body 51B. The shape and number of the liquid passage ports 54B can be appropriately set in consideration of the amount of the substance to be administered per time, the viscosity of the substance to be administered, and the like.
 基部52Bは、図5に示すように、内腔11Bの一部を溝状に切削し、この溝状部位に嵌合させて固定することができる。基部52Bは、内腔11Bに対し、接着剤などを用いて接着固定させてもよい。 As shown in FIG. 5, the base 52B can be fixed by cutting a part of the inner cavity 11B into a groove and fitting into the groove. The base portion 52B may be adhesively fixed to the inner cavity 11B using an adhesive or the like.
 上述した第2実施形態に係る投与装置100Bは、第1実施形態と同様に、投与対象に対する被投与物Xを充填した後、生体管腔に対し経皮的に導入される。図6Aは、投与装置100Bを生体内に留置した直後の状態を示している。 Similarly to the first embodiment, the administration device 100B according to the second embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance X to be administered. FIG. 6A shows the state immediately after the administration device 100B is placed in the living body.
 投与装置100Bは、図6Bに示すように、栓体40Bの移動により内腔11B内の内圧が放出圧力に達すると、弁体51Bは内腔11B内の被投与物Xや空気に押されて変形して先端部分が離隔し、放出口12Bを開放する。このとき、被投与物Xは、開放された放出口12Bから生体内に一定量だけ投与される。 In the administration device 100B, as shown in FIG. 6B, when the internal pressure in the lumen 11B reaches the release pressure due to movement of the stopper 40B, the valve body 51B is pushed by the object X and air in the lumen 11B. The tip portions are deformed and separated, opening the discharge port 12B. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12B.
 そして、投与装置100Bは、図6Cに示すように、一定量の被投与物Xの投与が終了して内腔11B内の内圧が放出圧力を下回ると、内腔11B内の空気の押圧力が弱まり、弁体51Bが元の姿勢に戻って弁体51Bの先端部分が閉じることで、放出口12Bを閉塞する。投与装置100Bは、内腔11B内の内圧が再び放出圧力に達するまで被投与物Xの投与は停止される。投与装置100Bは、上述した一連の動作を繰り返し行うことで、生体内に留置された状態で被投与物Xを間欠投与することができる。 Then, as shown in FIG. 6C, in the administration device 100B, when the administration of a certain amount of the substance It weakens, the valve body 51B returns to its original position, and the tip of the valve body 51B closes, thereby closing the discharge port 12B. In the administration device 100B, administration of the substance to be administered X is stopped until the internal pressure within the lumen 11B reaches the discharge pressure again. By repeatedly performing the series of operations described above, the administration device 100B can intermittently administer the substance to be administered X while being left in the living body.
 [第3実施形態]
 次に、第3実施形態に係る投与装置100Cについて図7~図9を適宜参照しながら説明する。
[Third embodiment]
Next, an administration device 100C according to the third embodiment will be described with reference to FIGS. 7 to 9 as appropriate.
 なお、第3実施形態に係る投与装置100Cにおいて、前述した第1実施形態や第2実施形態と同等の機能を有する構成要件については同一または関連する符号を付して詳細な説明を省略し、特に言及しない構成、部材、および使用方法などについては、前述した第1実施形態と同様のものとしてよい。 In addition, in the administration device 100C according to the third embodiment, constituent elements having the same functions as those in the first embodiment and the second embodiment described above are given the same or related numerals, and detailed explanations are omitted. Configurations, members, usage methods, etc. that are not particularly mentioned may be the same as those in the first embodiment described above.
 投与装置100Cは、図7に示すように、本体部10Cと、液体透過部20Cと、押圧部30Cと、栓体40Cと、開閉制御部50Cと、を備える。 As shown in FIG. 7, the administration device 100C includes a main body portion 10C, a liquid permeable portion 20C, a pressing portion 30C, a stopper 40C, and an opening/closing control portion 50C.
 投与装置100Cは、開閉制御部50Cの構成が第1実施形態の開閉制御部50Aや第2実施形態の開閉制御部50Bの構成と相違する。また、第3実施形態の投与装置100Cについても、第1、第2実施形態の投与装置100A、100Bと同様、押圧部30Cが非電気的に連続駆動して栓体40Cを押圧するが、生体内に留置したまま所定の投与条件に基づき被投与物Xの間欠的投与が可能な装置構成を有している。 In the administration device 100C, the configuration of the opening/closing control section 50C is different from the configuration of the opening/closing control section 50A of the first embodiment and the opening/closing control section 50B of the second embodiment. In addition, in the administration device 100C of the third embodiment, as in the administration devices 100A and 100B of the first and second embodiments, the pressing portion 30C is continuously driven non-electrically to press the stopper 40C. The device has a device configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions while it remains in the body.
 開閉制御部50Cは、図8に示すように、本体部10Cの先端側に配置され、放出口12Cを開放および閉塞閉可能な弁体51Cと、被投与物Xの通液口53Cが設けられる基部52Cと、一端が弁体51Cに接続され、他端が基部52Cに接続され、放出圧力よりも弱い引張力で弁体51Cを放出口12C側に引張する引張部54Cと、備えて構成される。開閉制御部50Cは、内腔11C内の内圧が所定の放出圧力に達したか否かに応じて放出口12Cを開放または閉塞する。 As shown in FIG. 8, the opening/closing control section 50C is disposed on the distal end side of the main body section 10C, and is provided with a valve body 51C that can open and close the discharge port 12C, and a liquid passage port 53C for the administered substance X. The valve body 52C is configured to include a base 52C, and a tensioning portion 54C, which has one end connected to the valve body 51C and the other end connected to the base 52C, and which pulls the valve body 51C toward the discharge port 12C with a tensile force weaker than the discharge pressure. Ru. The opening/closing control section 50C opens or closes the discharge port 12C depending on whether the internal pressure in the inner cavity 11C reaches a predetermined discharge pressure.
 弁体51Cは、放出口12Cを覆って閉塞する板状部材で構成される。弁体51Cは、引張部54Cと接続され、放出圧力よりも弱い引張力で放出口12C側に引張される。弁体51Cは、内腔11C内の内圧が放出圧力に達していない状態では引張部54Cの引張作用により放出口12Cを覆って閉塞した状態を維持する。弁体51Cは、閉塞時に内腔11Cと外部との連通を遮断できる性状を有していれば、形状や構成材料は特に限定されない。 The valve body 51C is composed of a plate-like member that covers and closes the discharge port 12C. The valve body 51C is connected to the tension portion 54C and is pulled toward the discharge port 12C with a tensile force that is weaker than the discharge pressure. When the internal pressure in the inner cavity 11C has not reached the release pressure, the valve body 51C covers the release port 12C and maintains the closed state due to the tensile action of the tension portion 54C. The shape and material of the valve body 51C are not particularly limited as long as the valve body 51C has properties that can cut off communication between the inner cavity 11C and the outside when closed.
 弁体51Cは、内腔11C内の内圧が放出圧力に達すると、引張部54Cの引張力に抗して放出口12Cから離隔する方向へ移動して放出口12Cを開放する(図9Bを参照)。また、弁体51Cは、一定量の被投与物Xの放出が終了して内腔11C内の内圧が放出圧力を下回ると、引張部54Cの引張作用により弁体51Cが引張されて放出口12Cを閉塞する(図9Cを参照)。なお、図9B、図9Cの白抜き矢印は、内腔11C内の内圧を示しており、図9Bでは内圧が放出圧力に達し、図9Cでは内圧が放出圧力を下回っていることを矢印の大小で表現している。 When the internal pressure within the lumen 11C reaches the release pressure, the valve body 51C moves in a direction away from the release port 12C against the tensile force of the tensioning portion 54C to open the release port 12C (see FIG. 9B). ). Further, when the discharge of a certain amount of the administered substance X is completed and the internal pressure in the inner cavity 11C becomes lower than the discharge pressure, the valve body 51C is pulled by the tensioning action of the tension portion 54C, and the discharge port 12C is pulled. (see Figure 9C). Note that the white arrows in FIGS. 9B and 9C indicate the internal pressure in the inner cavity 11C, and in FIG. 9B, the internal pressure has reached the discharge pressure, and in FIG. 9C, the internal pressure is below the discharge pressure. It is expressed as.
 基部52Cは、内腔11Cに固定され、引張部54Cを介して弁体51Cと接続される。基部52Cには、栓体40Cに押された被投与物Xが通過可能な通液口53Cが設けられる。通液口53Cの形状や個数については、被投与物Xの1回あたりの投与量や被投与物Xの粘性などを考慮して適宜設定することができる。 The base portion 52C is fixed to the inner cavity 11C and connected to the valve body 51C via the tension portion 54C. The base 52C is provided with a liquid passage port 53C through which the object X pressed by the stopper 40C can pass. The shape and number of the liquid passage ports 53C can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
 基部52Cは、図8に示すように、内腔11Cの一部を溝状に切削し、この溝状部位に嵌合させて固定することができる。基部52Cは、内腔11Cに対し、接着剤などを用いて接着固定させてもよい。 As shown in FIG. 8, the base 52C can be fixed by cutting a part of the inner cavity 11C into a groove and fitting into the groove. The base portion 52C may be adhesively fixed to the inner cavity 11C using an adhesive or the like.
 引張部54Cは、一端が弁体51Cと接続され、他端が基部52Cと接続され、ねじりコイルバネのように弾性収縮可能な弾性部材で構成される。引張部54Cは、放出圧力による押圧力よりも弱い引張力(弾性収縮力)で弁体51Cを放出口12C側に引張する。引張部54Cに引張される弁体51Cは、内腔11C内の内圧が放出圧力に達すると、放出口12Cから離隔する方向に押圧されて放出口12Cを開放し、内腔11Cの内圧が放出圧力を下回ると、引張部54Cの引張力により放出口12C側に引張されて放出口12Cを閉塞する。 The tension portion 54C has one end connected to the valve body 51C, the other end connected to the base portion 52C, and is made of an elastic member that can be elastically contracted like a torsion coil spring. The tensioning portion 54C pulls the valve body 51C toward the discharge port 12C with a tensile force (elastic contraction force) that is weaker than the pressing force due to the discharge pressure. When the internal pressure in the inner cavity 11C reaches the release pressure, the valve body 51C pulled by the tensioning part 54C is pressed in a direction away from the outlet 12C to open the outlet 12C, and the internal pressure in the inner cavity 11C is released. When the pressure drops below the pressure, the tensioning force of the tensioning portion 54C pulls the discharge port 12C toward the discharge port 12C, thereby closing the discharge port 12C.
 上述した第3実施形態に係る投与装置100Cは、第1、第2実施形態と同様に、投与対象に対する被投与物Xを充填した後、生体管腔に対し経皮的に導入される。図9Aは、投与装置100Cを生体内に留置した直後の状態を示している。 Similarly to the first and second embodiments, the administration device 100C according to the third embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance X to be administered. FIG. 9A shows the state immediately after the administration device 100C is placed in the living body.
 投与装置100Cは、図9Bに示すように、栓体40Cの移動により内腔11C内の内圧が放出圧力に達すると、弁体51Cは内腔11C内の被投与物Xや空気に押され、引張部54Cの引張力に抗して放出口12Cから離隔する方向に移動して放出口12Cを開放する。このとき、被投与物Xは、開放された放出口12Cから生体内に一定量だけ投与される。 In the administration device 100C, as shown in FIG. 9B, when the internal pressure in the lumen 11C reaches the release pressure due to the movement of the stopper 40C, the valve body 51C is pushed by the object X and air in the lumen 11C. It moves in a direction away from the discharge port 12C against the tensile force of the tension portion 54C to open the discharge port 12C. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12C.
 そして、投与装置100Cは、図9Cに示すように、一定量の被投与物Xの投与が終了して内腔11C内の内圧が放出圧力を下回ると、内腔11C内の空気の押圧力が弱まるため、引張部54Cの引張作用により弁体51Cが放出口12C側に引張されて放出口12Cを閉塞する。投与装置100Cは、内腔11C内の内圧が再び放出圧力に達するまで被投与物Xの投与は停止される。投与装置100Cは、上述した一連の動作を繰り返し行うことで、生体内に留置された状態で被投与物Xを間欠投与することができる。 Then, as shown in FIG. 9C, in the administration device 100C, when the administration of a certain amount of the substance Therefore, the valve body 51C is pulled toward the discharge port 12C by the tensioning action of the tension portion 54C, thereby closing the discharge port 12C. In the administration device 100C, administration of the substance to be administered X is stopped until the internal pressure in the lumen 11C reaches the discharge pressure again. By repeatedly performing the series of operations described above, the administration device 100C can intermittently administer the substance to be administered X while being left in the living body.
 [第4実施形態]
 次に、第4実施形態に係る投与装置100Dについて図10~図12を適宜参照しながら説明する。
[Fourth embodiment]
Next, an administration device 100D according to a fourth embodiment will be described with reference to FIGS. 10 to 12 as appropriate.
 第4実施形態に係る投与装置100Dは、前述した第3実施形態の変形例であり、間欠投与時の動作態様は同様となる。したがって、第3実施形態と同等の機能を有する構成要件については同一または関連する符号を付して詳細な説明を省略し、特に言及しない構成、部材、および使用方法などについては、前述した第3実施形態と同様のものとしてよい。 The administration device 100D according to the fourth embodiment is a modification of the third embodiment described above, and the operation mode during intermittent administration is the same. Therefore, constituent elements having the same functions as those in the third embodiment are given the same or related reference numerals, and detailed explanations are omitted. It may be similar to the embodiment.
 投与装置100Dは、図10に示すように、本体部10Dと、液体透過部20Dと、押圧部30Dと、栓体40Dと、開閉制御部50Dと、を備える。 As shown in FIG. 10, the administration device 100D includes a main body portion 10D, a liquid permeable portion 20D, a pressing portion 30D, a stopper 40D, and an opening/closing control portion 50D.
 投与装置100Dは、開閉制御部50Dの構成が第3実施形態の開閉制御部50Cの構成と相違する。また、第4実施形態の投与装置100Dについても、第1~第3実施形態の投与装置100A~100Cと同様、押圧部30Dが非電気的に連続駆動して栓体40Dを押圧するが、生体内に留置したまま所定の投与条件に基づき被投与物Xの間欠的投与が可能な装置構成を有している。 In the administration device 100D, the configuration of the opening/closing control section 50D is different from the configuration of the opening/closing control section 50C of the third embodiment. Also, in the administration device 100D of the fourth embodiment, the pressing portion 30D is continuously driven non-electrically to press the stopper 40D, as in the administration devices 100A to 100C of the first to third embodiments. The device has a device configuration that allows for intermittent administration of the substance to be administered based on predetermined administration conditions while it remains in the body.
 開閉制御部50Dは、図11に示すように、本体部10Dの先端側に配置され、放出口12Dを開放および閉塞閉可能な弁体51Dと、被投与物Xの通液口53Dが設けられる基部52Dと、一端が弁体51Dに接続され、他端が基部52Dに接続され、放出圧力よりも弱い引張力で弁体51Dを放出口12D側に引張する引張部54Dと、備えて構成される。開閉制御部50Dは、内腔11D内の内圧が所定の放出圧力に達したか否かに応じて放出口12Dを開放または閉塞する。 As shown in FIG. 11, the opening/closing control section 50D is disposed on the distal end side of the main body section 10D, and is provided with a valve body 51D that can open and close the discharge port 12D, and a liquid passage port 53D for the administered substance X. The valve body 52D is configured to include a base 52D, and a tensioning portion 54D, which has one end connected to the valve body 51D and the other end connected to the base 52D, and which pulls the valve body 51D toward the discharge port 12D with a tensile force weaker than the discharge pressure. Ru. The opening/closing control unit 50D opens or closes the discharge port 12D depending on whether the internal pressure within the lumen 11D reaches a predetermined discharge pressure.
 弁体51Dは、放出口12Dを覆って閉塞する板状部材で構成される。弁体51Dは、引張部54Dと接続され、放出圧力よりも弱い引張力で放出口12D側に引張される。弁体51Dは、内腔11D内の内圧が放出圧力に達していない状態では引張部54Dの引張作用により放出口12Dを覆って閉塞した状態を維持する。弁体51Dは、弁体51Cと同様、閉塞時に内腔11Dと外部との連通を遮断できる性状を有していれば、形状や構成材料は特に限定されない。 The valve body 51D is composed of a plate-like member that covers and closes the discharge port 12D. The valve body 51D is connected to the tensioning portion 54D and is pulled toward the discharge port 12D with a tensile force that is weaker than the discharge pressure. When the internal pressure within the lumen 11D has not reached the release pressure, the valve body 51D covers the release port 12D and maintains the closed state due to the tensile action of the tension portion 54D. Like the valve body 51C, the shape and constituent material of the valve body 51D are not particularly limited as long as the valve body 51D has properties that can cut off communication between the inner cavity 11D and the outside when closed.
 弁体51Dは、内腔11D内の内圧が放出圧力に達すると、引張部54Dの引張力に抗して放出口12Dから離隔する方向へ移動して放出口12Dを開放する(図12Bを参照)。また、弁体51Dは、一定量の被投与物Xの放出が終了して内腔11D内の内圧が放出圧力を下回ると、引張部54Dの引張作用により弁体51Dが引張されて放出口12Dを閉塞する(図12Cを参照)。なお、図12B、図12Cの白抜き矢印は、内腔11D内の内圧を示しており、図12Bでは内圧が放出圧力に達し、図12Cでは内圧が放出圧力を下回っていることを矢印の大小で表現している。 When the internal pressure in the lumen 11D reaches the release pressure, the valve body 51D moves in a direction away from the release port 12D against the tensile force of the tensioning portion 54D to open the release port 12D (see FIG. 12B). ). Further, when the discharge of a certain amount of the administered substance X is completed and the internal pressure in the inner cavity 11D becomes lower than the discharge pressure, the valve body 51D is pulled by the tensioning action of the tensioning portion 54D, and the discharge port 12D is pulled. (see Figure 12C). Note that the white arrows in FIGS. 12B and 12C indicate the internal pressure inside the lumen 11D, and in FIG. 12B, the internal pressure has reached the discharge pressure, and in FIG. 12C, the internal pressure is below the discharge pressure. It is expressed as.
 基部52Dは、内腔11Dに固定され、引張部54Dを介して弁体51Dと接続される。基部52Dには、栓体40Dに押された被投与物Xが通過可能な通液口53Dが設けられる。通液口53Dの形状や個数については、被投与物Xの1回あたりの投与量や被投与物Xの粘性などを考慮して適宜設定することができる。 The base portion 52D is fixed to the inner cavity 11D and connected to the valve body 51D via the tension portion 54D. The base 52D is provided with a liquid passage port 53D through which the object X pressed by the stopper 40D can pass. The shape and number of the liquid passage ports 53D can be appropriately set in consideration of the amount of the administered substance X per dose, the viscosity of the administered substance X, and the like.
 基部52Dは、図11に示すように、内腔11Dの一部を溝状に切削し、この溝状部位に嵌合させて固定することができる。基部52Dは、内腔11Dに対し、接着剤などを用いて接着固定させてもよい。 As shown in FIG. 11, the base 52D can be fixed by cutting a part of the inner cavity 11D into a groove and fitting into the groove. The base portion 52D may be adhesively fixed to the inner cavity 11D using an adhesive or the like.
 引張部54Dは、弁体51Dに接続される第1磁性体541Dと、基部52Dとで構成される。基部52は、第2磁性体542Dとして機能する。第1磁性体541Dは、基部52Dから先端側に延在する非磁性体の支持部521Dと嵌合し、内腔11Dの軸方向に沿って相対移動可能に配置される。第1磁性体541Dと第2磁性体542Dは、互いに異なる磁極(N極またはS極)を有しており、放出圧力よりも弱い引張力(磁気的吸引力)を発生する。引張部54Dに引張される弁体51Dは、内腔11D内の内圧が放出圧力に達すると、放出口12Dから離隔する方向に押圧されて放出口12Dを開放し、内腔11Dの内圧が放出圧力を下回ると、引張部54Dの引張力により放出口12D側に引張されて放出口12Dを閉塞する。 The tension portion 54D is composed of a first magnetic body 541D connected to the valve body 51D and a base portion 52D. The base 52 functions as a second magnetic body 542D. The first magnetic body 541D is fitted into a non-magnetic support portion 521D extending from the base 52D to the distal end side, and is arranged so as to be relatively movable along the axial direction of the inner cavity 11D. The first magnetic body 541D and the second magnetic body 542D have different magnetic poles (N pole or S pole), and generate a tensile force (magnetic attractive force) that is weaker than the discharge pressure. When the internal pressure in the inner cavity 11D reaches the release pressure, the valve body 51D pulled by the tensioning part 54D is pressed in a direction away from the outlet 12D to open the outlet 12D, and the internal pressure in the inner cavity 11D is released. When the pressure drops below the pressure, the tensioning force of the tensioning portion 54D pulls the discharge port 12D toward the discharge port 12D, thereby closing the discharge port 12D.
 上述した第4実施形態に係る投与装置100Dは、第1~第3実施形態と同様に、投与対象に対する被投与物Xを充填した後、生体管腔に対し経皮的に導入される。図12Aは、投与装置100Dを生体内に留置した直後の状態を示している。 Similarly to the first to third embodiments, the administration device 100D according to the fourth embodiment described above is percutaneously introduced into a living body lumen after being filled with the substance to be administered X to be administered. FIG. 12A shows the state immediately after the administration device 100D is placed in the living body.
 投与装置100Dは、図12Bに示すように、栓体40Dの移動により内腔11D内の内圧が放出圧力に達すると、弁体51Dは内腔11D内の被投与物Xや空気に押され、引張部54Dの引張力に抗して放出口12Dから離隔する方向に移動して放出口12Dを開放する。このとき、被投与物Xは、開放された放出口12Dから生体内に一定量だけ投与される。 In the administration device 100D, as shown in FIG. 12B, when the internal pressure in the lumen 11D reaches the release pressure due to the movement of the stopper 40D, the valve body 51D is pushed by the substance X and air in the lumen 11D, The discharge port 12D is opened by moving in a direction away from the discharge port 12D against the tensile force of the tension portion 54D. At this time, a certain amount of the administered substance X is administered into the living body from the opened discharge port 12D.
 そして、投与装置100Dは、図12C示すように、一定量の被投与物Xの投与が終了して内腔11D内の内圧が放出圧力を下回ると、内腔11D内の空気の押圧力が弱まるため、引張部54Dの引張作用により弁体51Dが放出口12D側に引張されて放出口12Dを閉塞する。投与装置100Dは、内腔11D内の内圧が再び放出圧力に達するまで被投与物Xの投与は停止される。投与装置100Dは、上述した一連の動作を繰り返し行うことで、生体内に留置された状態で被投与物Xを間欠投与することができる。 Then, in the administration device 100D, as shown in FIG. 12C, when the administration of a certain amount of the object X is finished and the internal pressure in the lumen 11D becomes lower than the discharge pressure, the pressing force of the air in the lumen 11D weakens. Therefore, the valve body 51D is pulled toward the discharge port 12D by the tensioning action of the tension portion 54D, thereby closing the discharge port 12D. In the administration device 100D, administration of the substance to be administered X is stopped until the internal pressure within the lumen 11D reaches the discharge pressure again. By repeatedly performing the above-described series of operations, the administration device 100D can intermittently administer the substance to be administered while the administration device 100D is left in the living body.
 [作用効果]
 以上説明したように、本実施形態に係る投与装置100A~100Dは、生体内に放出される被投与物Xが収容可能な内腔11A~11Dを有し、先端に被投与物Xの放出口12A~12Dが形成される本体部10A~10Dと、内腔11A~11D内を液密に摺動可能な栓体40A~40Dと、内腔11A~11Dにおいて栓体40A~40Dより上流側に配置され、非電気的に連続駆動して栓体40A~40Dを下流側に押圧する押圧部30A~30Dと、本体部10A~10Dの先端側に配置され、内腔11A~11Dの内圧が所定の放出圧力に達すると、放出口12A~12Dを開放して被投与物Xの放出を許容し、一定量の被投与物Xを放出して内腔11A~11Dの内圧が放出圧力を下回ると、放出口12A~12Dを閉塞して被投与物Xの放出を制限する開閉制御部50A~50Dとを備える。
[Effect]
As explained above, the administration devices 100A to 100D according to the present embodiment have internal cavities 11A to 11D that can accommodate the administered substance X to be released into the living body, and have a discharge port for the administered substance X at the tip. 12A to 12D are formed, plugs 40A to 40D that can slide liquid-tightly inside the lumens 11A to 11D, and plugs 40A to 40D that are upstream of the plugs 40A to 40D in the lumens 11A to 11D. Pressing parts 30A to 30D are arranged and continuously driven non-electrically to push the stoppers 40A to 40D downstream, and pressure parts 30A to 30D are arranged at the distal ends of the main bodies 10A to 10D to maintain the internal pressure of the lumens 11A to 11D at a predetermined level. When the discharge pressure reaches the discharge pressure, the discharge ports 12A to 12D are opened to allow the discharge of the administered substance , opening/closing control units 50A to 50D that close the discharge ports 12A to 12D to restrict release of the administered substance X.
 投与装置100A~100Dは、従来の持続投与装置の構成を利用し、放出部の代わりに開閉制御部50A~50Dを本体部10A~10Dの先端側に配置した構成を有する。投与装置100A~100Dの押圧部30A~30Dは、非電気的に連続駆動する構成であり、開閉制御部50A~50Dは、圧力応答性を有し、内腔11A~11D内の内圧が被投与物Xの投与条件に合わせて設定された放出圧力に達したときに作動し、被投与物Xを生体内に間欠的に放出することができる。そのため、投与装置100A~100Dは、電気的な駆動機構を搭載することなく、間欠投与が好ましい被投与物を適切な投与間隔で間欠投与することができる。また、投与装置100A~100Dは、従来の装置構成を活かして先端部分を一部変更するだけでよいため、製造上の観点からも有効である。 The administration devices 100A to 100D utilize the structure of a conventional continuous administration device, and have opening/closing control sections 50A to 50D arranged on the distal end side of the main body sections 10A to 10D instead of the ejection section. The pressing parts 30A to 30D of the administration devices 100A to 100D are configured to be non-electrically driven continuously, and the opening/closing control parts 50A to 50D have pressure responsiveness, so that the internal pressure within the lumens 11A to 11D is controlled by the administered body. It is activated when a release pressure set according to the administration conditions of the substance X is reached, and the substance to be administered can be intermittently released into the living body. Therefore, the administration devices 100A to 100D are capable of intermittently administering a substance to be administered which is preferably administered intermittently at appropriate administration intervals without being equipped with an electrical drive mechanism. In addition, the administration devices 100A to 100D are effective from a manufacturing point of view because they utilize the conventional device configuration and require only a partial change in the tip portion.
 また、本実施形態に係る投与装置100Aにおいて、開閉制御部50Aは、放出口12Aの軸方向に延在する軸部511Aと、軸部511Aの先端側の周囲に形成され、放出口12Aを覆うように閉塞する閉塞部512Aと、を含み、内腔11Aの内圧が放出圧力に達すると、閉塞部512Aの一部が放出口12Aから離隔して放出口12Aを開放し、被投与物Xの放出により内腔11Aの内圧が放出圧力を下回ると、閉塞部512Aの一部が放出口12Aに接近して放出口12Aを閉塞するように構成してもよい。 In addition, in the administration device 100A according to the present embodiment, the opening/closing control unit 50A is formed around a shaft portion 511A extending in the axial direction of the discharge port 12A and a distal end side of the shaft portion 511A, and covers the discharge port 12A. When the internal pressure of the lumen 11A reaches the release pressure, a part of the occlusion part 512A separates from the ejection port 12A to open the ejection port 12A, and the object to be administered X is released. When the internal pressure of the lumen 11A becomes lower than the release pressure due to release, a part of the closing portion 512A may approach the release port 12A and close the release port 12A.
 このような構成により、投与装置100Aは、内腔11A内の内圧が放出圧力に達すると、閉塞部512Aの一部が放出口12Aを開放して被投与物Xの放出を許容し、内圧が放出圧力を下回ると、閉塞部512Aの離隔部分が放出口12Aを閉塞して被投与物Xの放出を制限することができる。そのため、投与装置100Aは、非電気的に連続駆動する構成となるが、生体内に留置したまま被投与物Xを間欠投与することができる。 With such a configuration, in the administration device 100A, when the internal pressure in the lumen 11A reaches the release pressure, a part of the closing part 512A opens the release port 12A to allow the release of the administered substance X, and the internal pressure is reduced. When the discharge pressure is lower than the discharge pressure, the separated portion of the closing portion 512A can close the discharge port 12A and restrict the discharge of the administered substance X. Therefore, although the administration device 100A is configured to be continuously driven non-electrically, it is possible to intermittently administer the substance to be administered X while remaining in the living body.
 また、本実施形態に係る投与装置100Bにおいて、開閉制御部50Bは、先端に向かって徐々に軸中心で収束するように傾斜して延在する一対の弁体51Bと、弁体51Bの先端が接することにより形成される開閉可能なスリット53Bと、被投与物Xが流入する側に設けられた通液口54Bと、通液口54Bをスリット53Bに接続する流路55Bと、を含み、内腔11Bの内圧が放出圧力に達すると、弁体51Bの変形によりスリット53Bが開いて放出口12Bを開放し、被投与物Xの放出により内腔11Bの内圧が放出圧力を下回ると、弁体51Bが変形前の形状に戻ってスリット53Bが閉じて放出口12Bを閉塞する構成にしてもよい。 In addition, in the administration device 100B according to the present embodiment, the opening/closing control unit 50B includes a pair of valve bodies 51B that extend in an inclined manner so as to gradually converge at the axial center toward the distal end, and a distal end of the valve body 51B. It includes an openable and closable slit 53B formed by contacting each other, a liquid passage port 54B provided on the side into which the administered substance X flows, and a flow path 55B connecting the liquid passage port 54B to the slit 53B. When the internal pressure of the cavity 11B reaches the discharge pressure, the slit 53B opens due to the deformation of the valve body 51B, opening the discharge port 12B. When the internal pressure of the cavity 11B falls below the discharge pressure due to the discharge of the administered substance X, the valve body It may be configured such that 51B returns to its pre-deformed shape and slit 53B closes to close discharge port 12B.
 このような構成により、投与装置100Bは、内腔11B内の内圧が放出圧力に達すると、弁体51Bの先端部分が離隔してスリット53Bが開き、放出口12Bを開放して被投与物Xの放出を許容し、内圧が放出圧力を下回ると、弁体51Bの先端部分が変形前の形状に戻ってスリット53Bが閉じ、放出口12Bを閉塞して被投与物Xの放出を制限することができる。そのため、投与装置100Bは、非電気的に連続駆動する構成となるが、生体内に留置したまま被投与物Xを間欠投与することができる。 With such a configuration, in the administration device 100B, when the internal pressure in the lumen 11B reaches the release pressure, the distal end portion of the valve body 51B is separated, the slit 53B is opened, the release port 12B is opened, and the administered material X is released. When the internal pressure becomes lower than the release pressure, the tip of the valve body 51B returns to the shape before deformation, the slit 53B closes, and the release port 12B is closed to restrict the release of the administered substance X. Can be done. Therefore, although the administration device 100B is configured to be continuously driven non-electrically, it is possible to intermittently administer the substance to be administered X while remaining in the living body.
 また、本実施形態に係る投与装置100C、100Dにおいて、開閉制御部50C、50Dは、放出口12C、12Dを覆うように閉塞する弁体51C、51Dと、被投与物Xの通液口53C、53Dが設けられる基部52C、52Dと、一端が弁体51C、51Dに接続され、他端が基部52C、52Dに接続され、放出圧力よりも弱い引張力で弁体51C、51Dを放出口12C、12D側に引張する引張部54C、54Dと、を含み、内腔11C、11Dの内圧が放出圧力に達すると、弁体51C、51Dが放出口12C、12Dから離隔して放出口12C、12Dを開放し、被投与物Xの放出により内腔11C、11Dの内圧が放出圧力を下回ると、弁体51C、51Dが放出口12C、12Dに接近して放出口12C、12Dを閉塞する構成にしてもよい。 In addition, in the administration devices 100C and 100D according to the present embodiment, the opening/closing control units 50C and 50D include valve bodies 51C and 51D that close to cover the discharge ports 12C and 12D, a liquid passage port 53C for the administered object X, 53D are provided, one end is connected to the valve body 51C, 51D, the other end is connected to the base 52C, 52D, and the valve body 51C, 51D is connected to the discharge port 12C, with a tensile force weaker than the discharge pressure. When the internal pressure of the inner cavities 11C and 11D reaches the discharge pressure, the valve bodies 51C and 51D are separated from the discharge ports 12C and 12D, and the valve bodies 51C and 51D are separated from the discharge ports 12C and 12D. When the internal pressure of the inner cavities 11C and 11D becomes lower than the discharge pressure due to release of the administered substance X, the valve bodies 51C and 51D approach the discharge ports 12C and 12D to close the discharge ports 12C and 12D. Good too.
 このような構成により、投与装置100C、100Dは、内腔11C、11D内の内圧が放出圧力に達すると、弁体51C、51Dが放出口12Aから離隔して被投与物Xの放出を許容し、内圧が放出圧力を下回ると、引張部54C、54Dの引張作用により弁体51C、51Dで放出口12C、12Dを閉塞して被投与物Xの放出を制限することができる。そのため、投与装置100C、100Dは、非電気的に連続駆動する構成となるが、生体内に留置したまま被投与物Xを間欠投与することができる。 With such a configuration, in the administration devices 100C and 100D, when the internal pressure in the lumens 11C and 11D reaches the release pressure, the valve bodies 51C and 51D are separated from the release port 12A to allow the release of the administered substance X. When the internal pressure is lower than the release pressure, the release ports 12C and 12D can be closed by the valve bodies 51C and 51D due to the tensioning action of the tension portions 54C and 54D, thereby restricting the release of the administered substance X. Therefore, although the administration devices 100C and 100D are configured to be continuously driven non-electrically, they can intermittently administer the substance to be administered while remaining in the living body.
 本出願は、2022年3月25日に出願された日本国特許出願第2022-049285号に基づいており、その開示内容は、参照により全体として引用されている。 This application is based on Japanese Patent Application No. 2022-049285 filed on March 25, 2022, the disclosure content of which is incorporated by reference in its entirety.
 10A、10B、10C、10D 本体部
 11A、11B、11C、11D 内腔、
 12A、12B、12C、12D 放出口、
 20A、20B、20C、20D 液体透過部、
 30A、30B、30C、30D 押圧部、
 40A、40B、40C、40D 栓体、
 50A、50B、50C、50D 開閉制御部、
 51A、51B、51C、51D 弁体、
 52C、52D 基部、
 53B スリット、
 54B、53C、53D 通液口、
 54C、54D 引張部、
 55B 流路、
 X 被投与物、
 Y1 第1空間、
 Y2 第2空間。
10A, 10B, 10C, 10D main body 11A, 11B, 11C, 11D lumen,
12A, 12B, 12C, 12D outlet,
20A, 20B, 20C, 20D liquid transmission part,
30A, 30B, 30C, 30D pressing part,
40A, 40B, 40C, 40D plug body,
50A, 50B, 50C, 50D opening/closing control section,
51A, 51B, 51C, 51D valve body,
52C, 52D base,
53B slit,
54B, 53C, 53D liquid port,
54C, 54D tension part,
55B flow path,
X administered substance,
Y1 first space,
Y2 2nd space.

Claims (4)

  1.  生体内に放出される被投与物が収容可能な内腔を有し、先端に前記被投与物の放出口が形成される本体部と、
     前記内腔内を液密に摺動可能な栓体と、
     前記内腔において前記栓体より上流側に配置され、非電気的に連続駆動して前記栓体を下流側に押圧する押圧部と、
     前記本体部の先端側に配置され、前記内腔の内圧が所定の放出圧力に達すると、前記放出口を開放して前記被投与物の放出を許容し、一定量の前記被投与物を放出して前記内腔の内圧が前記放出圧力を下回ると、前記放出口を閉塞して前記被投与物の放出を制限する開閉制御部と、
     を備える、投与装置。
    a main body portion having a lumen capable of accommodating a substance to be administered to be released into a living body, and a discharge port for the substance to be administered is formed at the tip;
    a plug that can slide fluid-tightly within the lumen;
    a pressing part that is disposed upstream of the plug in the inner cavity and continuously drives the plug in a non-electrical manner to press the plug downstream;
    Disposed on the distal end side of the main body, when the internal pressure of the lumen reaches a predetermined release pressure, the discharge port is opened to allow release of the administered substance, and a predetermined amount of the administered substance is released. an opening/closing control unit that closes the discharge port to limit release of the administered substance when the internal pressure of the inner cavity becomes lower than the discharge pressure;
    A dosing device comprising:
  2.  前記開閉制御部は、
     前記放出口の軸方向に延在する軸部と、
     前記軸部の先端側の周囲に形成され、前記放出口を覆うように閉塞する閉塞部と、
     を含み、
     前記内腔の内圧が前記放出圧力に達すると、前記閉塞部の一部が前記放出口から離隔して前記放出口を開放し、
     前記被投与物の放出により前記内腔の内圧が前記放出圧力を下回ると、前記閉塞部の離隔部分が前記放出口に接近して前記放出口を閉塞する、請求項1に記載の投与装置。
    The opening/closing control section is
    a shaft portion extending in the axial direction of the discharge port;
    a closing part formed around the distal end side of the shaft part and closing the discharge port so as to cover it;
    including;
    When the internal pressure of the lumen reaches the discharge pressure, a part of the blocking part separates from the discharge port to open the discharge port;
    The administration device according to claim 1, wherein when the internal pressure of the lumen becomes lower than the discharge pressure due to discharge of the administration object, the separated portion of the closing portion approaches the discharge port and closes the discharge port.
  3.  前記開閉制御部は、
     先端に向かって徐々に軸中心で収束するように傾斜して延在する一対の弁体と、
     前記弁体の先端が接することにより形成される開閉可能なスリットと、
     前記被投与物が流入する側に設けられた通液口と、
     前記通液口を前記スリットに接続する流路と、を含み、
     前記内腔の内圧が前記放出圧力に達すると、前記弁体の変形により前記スリットが開いて前記放出口を開放し、
     前記被投与物の放出により前記内腔の内圧が前記放出圧力を下回ると、前記弁体が変形前の形状に戻って前記スリットが閉じて前記放出口を閉塞する、請求項1に記載の投与装置。
    The opening/closing control section is
    a pair of valve bodies extending at an angle so as to gradually converge at the axial center toward the tip;
    an openable and closable slit formed by the tips of the valve bodies coming into contact with each other;
    a liquid passage port provided on the side into which the substance to be administered flows;
    a flow path connecting the liquid passage port to the slit,
    When the internal pressure of the inner cavity reaches the discharge pressure, the slit opens due to deformation of the valve body and opens the discharge port;
    The administration according to claim 1, wherein when the internal pressure of the lumen becomes lower than the release pressure due to release of the administered substance, the valve body returns to the shape before deformation, the slit closes, and the release port is closed. Device.
  4.  前記開閉制御部は、
     前記放出口を覆うように閉塞する弁体と、
     前記被投与物の通液口が設けられる基部と、
     一端が前記基部に接続され、他端が前記弁体に接続され、前記放出圧力よりも弱い引張力で前記弁体を前記放出口側に引張する引張部と、を含み、
     前記内腔の内圧が前記放出圧力に達すると、前記弁体が前記放出口から離隔して前記放出口を開放し、
     前記被投与物の放出により前記内腔の内圧が前記放出圧力を下回ると、前記弁体が前記放出口に接近して前記放出口を閉塞する、請求項1に記載の投与装置。
    The opening/closing control section is
    a valve body that closes to cover the discharge port;
    a base portion provided with a liquid passage port for the administered substance;
    a tensioning part, one end of which is connected to the base, the other end of which is connected to the valve body, and which pulls the valve body toward the discharge port side with a tensile force that is weaker than the discharge pressure;
    When the internal pressure of the inner cavity reaches the discharge pressure, the valve body separates from the discharge port to open the discharge port;
    The administration device according to claim 1, wherein when the internal pressure of the inner cavity becomes lower than the discharge pressure due to discharge of the administration object, the valve body approaches the discharge port and closes the discharge port.
PCT/JP2023/009313 2022-03-25 2023-03-10 Administration device WO2023181996A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-049285 2022-03-25
JP2022049285 2022-03-25

Publications (1)

Publication Number Publication Date
WO2023181996A1 true WO2023181996A1 (en) 2023-09-28

Family

ID=88101313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/009313 WO2023181996A1 (en) 2022-03-25 2023-03-10 Administration device

Country Status (1)

Country Link
WO (1) WO2023181996A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
JP2001510792A (en) * 1997-07-25 2001-08-07 アルザ・コーポレーション Osmotic dosing flow modulator device
JP2002513414A (en) * 1997-03-24 2002-05-08 アルザ・コーポレイション Implantable delivery device with self-adjustable outlet port
JP2005515805A (en) * 2001-11-21 2005-06-02 アルザ・コーポレーション Osmotic delivery device with two-way valve and dynamic self-regulating flow channel
US20110311607A1 (en) * 2010-06-18 2011-12-22 Coldren Bret A Punctal plugs with continuous or pulsatile drug release mechanism

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
JP2002513414A (en) * 1997-03-24 2002-05-08 アルザ・コーポレイション Implantable delivery device with self-adjustable outlet port
JP2001510792A (en) * 1997-07-25 2001-08-07 アルザ・コーポレーション Osmotic dosing flow modulator device
JP2005515805A (en) * 2001-11-21 2005-06-02 アルザ・コーポレーション Osmotic delivery device with two-way valve and dynamic self-regulating flow channel
US20110311607A1 (en) * 2010-06-18 2011-12-22 Coldren Bret A Punctal plugs with continuous or pulsatile drug release mechanism

Similar Documents

Publication Publication Date Title
JP5827246B2 (en) Sustained release liquid drug delivery device
US6902544B2 (en) Troubleshooting accelerator system for implantable drug delivery pumps
US9381299B2 (en) Implantable drug delivery devices
US6491663B1 (en) Medical devices using electrosensitive gels
RU2633228C1 (en) Cartridge for fluid supply to transmermal drug delivery device (versions)
US20030069541A1 (en) Implantable device for access to a treatment site
KR20010031745A (en) Intravesical Infuser
JP2001505087A (en) Needleless injection site
CN112516441B (en) Device for the temporary topical application of a fluid
JPWO2008007422A1 (en) Chemical solution continuous infusion device
WO2023181996A1 (en) Administration device
JP5241045B2 (en) Connector valve body and connector
WO2023085144A1 (en) Administration device
JP2003518421A (en) Osmotic beneficial agent delivery system
WO2023080251A1 (en) Medical instrument
WO2023181997A1 (en) Continuous administering device
WO2024075723A1 (en) Drug administration device
CN112516433B (en) Device for the temporary topical application of a fluid
JP2001104477A (en) Liquid drug sustained injection device
KR100955581B1 (en) Medical substances injecting device using gas pressure
Young Implications of Affinity-Based Drug Refilling into Poly (lactic-co-glycolic acid) Polymers
CN117138215A (en) Passive self-driven micro-delivery device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23774595

Country of ref document: EP

Kind code of ref document: A1